


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:29Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406196" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406196</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="e26717344" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406196</article-id><article-id pub-id-type="pmcid-ver">PMC12406196.1</article-id><article-id pub-id-type="pmcaid">12406196</article-id><article-id pub-id-type="pmcaiid">12406196</article-id><article-id pub-id-type="pmid">40778743</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c01602</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Anticoronavirus
Activity of Uridine Glycoconjugates
Containing a 1,2,3-Triazole Moiety</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7689828</contrib-id><name name-style="western"><surname>Graul</surname><given-names initials="M">Malgorzata</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7689829</contrib-id><name name-style="western"><surname>Brzuska</surname><given-names initials="G">Gabriela</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7689832</contrib-id><name name-style="western"><surname>Wisniewska</surname><given-names initials="E">Ewa</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7689834</contrib-id><name name-style="western"><surname>Dominska</surname><given-names initials="M">Monika</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7031447</contrib-id><name name-style="western"><surname>Strakova</surname><given-names initials="P">Petra</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3488604</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4655-2380</contrib-id><name name-style="western"><surname>Ruzek</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff5" ref-type="aff"/><xref rid="aff6" ref-type="aff"/><xref rid="aff7" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7487210</contrib-id><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names initials="G">Gabriela</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6631519</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8573-4254</contrib-id><name name-style="western"><surname>Krol</surname><given-names initials="E">Ewelina</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Laboratory
of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">49646</institution-id><institution>University of Gdansk and Medical University of Gdansk</institution></institution-wrap>, <addr-line>Abrahama 58</addr-line>, <city>Gdansk</city>
<postal-code>80-307</postal-code>, <country country="PL">Poland</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Laboratory
of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology</institution>, <institution>University of Gdansk and Medical University of Gdansk</institution>, <addr-line>Abrahama 58</addr-line>, <city>Gdansk</city>
<postal-code>80-307</postal-code>, <country country="PL">Poland</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Department
of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Faculty
of Chemistry</institution>, <institution>Silesian University of Technology</institution>, <addr-line>Krzywoustego 4</addr-line>, <city>Gliwice</city>
<postal-code>44-100</postal-code>, <country country="PL">Poland</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Biotechnology
Center</institution>, <institution>Silesian University of Technology</institution>, <addr-line>Krzywoustego 8</addr-line>, <city>Gliwice</city>
<postal-code>44-100</postal-code>, <country country="PL">Poland</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">Laboratory
of Emerging Viral Diseases</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">48357</institution-id><institution>Veterinary Research
Institute</institution></institution-wrap>, <addr-line>Hudcova 70</addr-line>, <city>Brno</city>
<postal-code>CZ-62100</postal-code>, <country country="CZ">Czech Republic</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">Department
of Experimental Biology, Faculty of Science</institution>, <institution>Masaryk University</institution>, <addr-line>Kamenice 735</addr-line>, <city>Brno</city>
<postal-code>CZ-62500</postal-code>, <country country="CZ">Czech Republic</country>
</aff><aff id="aff7">
<label>&#8711;</label>
<institution content-type="dept">Laboratory
of Emerging Viral Infections</institution>, <institution>Veterinary
Research Institute</institution>, <addr-line>Hudcova
296</addr-line>, <city>Brno</city>
<postal-code>CZ-62100</postal-code>, <country country="CZ">Czech Republic</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>ewelina.krol@biotech.ug.edu.pl</email>. Tel: <phone>+48-58-523-63-83</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>08</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17859</fpage><lpage>17873</lpage><history><date date-type="received"><day>10</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>7</month><year>2025</year></date><date date-type="online"><day>08</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-08"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-08">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c01602.pdf"/><abstract><p>Coronaviruses can
spread rapidly to new host species and cause
severe respiratory and enteric diseases in vertebrates, including
humans. To date, seven coronaviruses have been identified in humans,
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
being the most notorious due to its substantial social and economic
impact. Although anti-SARS-CoV-2 vaccines are available, infections
remain widespread, highlighting the ongoing need for antiviral treatments.
Here, we report the synthesis and evaluation of the activity of uridine
glycoconjugates, designed as glycosyltransferase donor-type inhibitors
incorporating a 1,2,3-triazole moiety. These compounds were tested
against two model coronaviruses: murine hepatitis virus strain A59
(MHV) and human coronavirus strain NL63 (HCoV-NL63). Four of the synthesized
compounds demonstrated strong antiviral activity against both viruses,
and their efficacy was further confirmed against SARS-CoV-2. Our results
suggest that these compounds interfere with the coronavirus infectivity
and replication process. Thus, these novel compounds may prove to
be effective broad-spectrum antiviral inhibitors.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c01602_0009.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c01602_0007.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>NextGenerationEU</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100031478</institution-id></institution-wrap></funding-source><award-id>LX22NPO5103</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Narodowe Centrum Nauki</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004281</institution-id></institution-wrap></funding-source><award-id>UMO-2020/01/0/NZ6/00146</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Narodowe Centrum Nauki</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004281</institution-id></institution-wrap></funding-source><award-id>UMO-2021/41/B/NZ6/02628</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c01602</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c01602</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>effe27d623c53c7e1f70667ae9f9a2896097076be6f39d2f2fec7d162ffc71be</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Coronaviruses (CoVs) are
large, enveloped, single-stranded RNA
viruses that infect a variety of vertebrates, including humans, and
are responsible for both respiratory and enteric diseases. They are
classified into four genera: &#945;-, &#946;-, &#947;-, and delta-coronaviruses.
To date, seven CoVs have been identified in humans. Among them, the
&#945;-CoVs HCoV-229E and HCoV-NL63, along with the &#946;-CoVs
HCoV-OC43 and HCoV-HKU1, are generally associated with mild respiratory
infections, though more severe cases can occur.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> Three
highly pathogenic &#946;-CoVs&#58872;SARS-CoV, MERS-CoV, and SARS-CoV-2&#58872;are
known to cause severe respiratory and systemic infections, presenting
significant public health risks.<xref rid="ref3" ref-type="bibr"/>
</p><p>The SARS-CoV-2 pandemic, which began in December 2019, has resulted
in more than 600 million infections and more than 7 million deaths
globally, resulting in profound social and economic consequences.
Due to the biosafety requirements for handling SARS-CoV-2 (biosafety
level 3 laboratory), antiviral studies often rely on model viruses,
such as murine hepatitis virus (MHV) and human HCoV-NL63, which offer
valuable insights into CoV replication cycle and antiviral efficacy.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> MHV, a &#946;-CoV like SARS-CoV-2, infects mice and shares several
characteristics with human-pathogenic CoVs. Although evolutionarily
more distant, HCoV-NL63 uses the same ACE2 receptor for cellular entry
as SARS-CoV-2, making it a valuable model for research. In response
to the SARS-CoV-2 pandemic, a wide range of vaccines employing various
mechanisms, including mRNA, DNA, and viral vector approaches, have
been developed. However, FDA-approved antiviral treatments remain
limited, with only remdesivir (Veklury) and baricitinib (Olumiant)
authorized, along with emergency-use therapies such as molnupiravir
(Lagevrio) and Paxlovid.<xref rid="ref9" ref-type="bibr"/> As the need for
new broad-spectrum antivirals remains critical, targeting multiple
steps of the viral life cycle is expected to be a key strategy, especially
in light of the potential for future CoV outbreaks.</p><p>The spike
(S) glycoprotein of all coronaviruses is highly glycosylated,
with more than 20 predicted <italic toggle="yes">N</italic>-glycosylation sites
in a monomeric protein.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>&#8722;<xref rid="ref11" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref12" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref13" ref-type="bibr"/>
</named-content> It was confirmed by mass spectrometry that SARS-CoV-2
S protein contains 3 <italic toggle="yes">O</italic>-glycosylation sites and 22 <italic toggle="yes">N</italic>-glycosylation sites.<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content> The predominant
types of <italic toggle="yes">N</italic>-glycans are complex and hybrid, with only
8 sites bearing oligomannose-type glycans. The glycosylation of other
structural proteins of SARS-CoV-2 has not yet been studied. Notably,
glycosylation of the S protein, mediated by host cell glycosyltransferases
(GTs), plays a critical role in proper protein folding and interaction
with the ACE2 receptor.<xref rid="ref15" ref-type="bibr"/> Inhibitors that
mimic natural GT substrates offer promising antiviral potential. Natural
GT donor-type substrates typically consist of a sugar unit linked
to uridine via a diphosphate moiety in their structure, which interacts
with a bivalent metal ion present in the active center of the enzyme.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> Based on this, we designed and synthesized a panel of uridine-based
glycoconjugates as GT inhibitors, replacing the diphosphate group
with a noncharged linker capable of coordinating with the divalent
metal ions necessary for GT function. This study evaluates the antiviral
activity of these compounds against MHV, HCoV-NL63 and SARS-CoV-2,
identifying four with potent activity.</p></sec><sec id="sec2"><label>2</label><title>Results</title><sec id="sec2.1"><label>2.1</label><title>Synthesis of Glycoconjugates Type I&#8211;VI</title><p>Taking
into account previous findings regarding the influence of
structural modifications in uridine glycoconjugates on their activity,<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>&#8722;<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content> we aimed to explore how further structural modifications to the
linker between sugar and uridine might affect the antiviral activity
of these compounds against selected coronaviruses.</p><p>To this end,
six types of uridine glycoconjugates (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) containing a 1,2,3-triazole ring in the
linker structure were synthesized. These compounds differ in the type
of heteroatom at the anomeric position of the sugar (oxygen for type <bold>I</bold> or <bold>II</bold>, nitrogen for type <bold>III</bold> and
sulfur for types <bold>IV</bold>&#8211;<bold>VI</bold>). Additionally,
the glycoconjugates vary in the nature of the linker bonds: type <bold>I</bold> contains only an ether bond, type <bold>II</bold> has an
ether and an amide bond, type <bold>III</bold> includes two amide
bonds, type <bold>IV</bold> has a thioether bond, type <bold>V</bold> features both a thioether and an amide bond, and type <bold>VI</bold> contains a thioether and an ether bond. The presence of heteroatoms
like oxygen or sulfur and an amide bond, common in many biologically
active compounds, is expected to enhance the chelating ability of
these uridine glycoconjugates, thereby increasing their affinity for
metal-dependent glycosyltransferases.<xref rid="ref21" ref-type="bibr"/> Additionally, the orientation of the 1,2,3-triazole ring, formed
by the reaction of the azides with propargyl derivatives of both linked
parts, varies among the compounds. The sugars used for the glycoconjugating
uridine are <sc>d</sc>-glucose and <sc>d</sc>-galactose derivatives,
allowing us to assess the impact of the sugar moiety type on the activity
and selectivity of the obtained conjugates. All synthesized uridine
glycoconjugates contain a sugar part protected by acetyl groups, and
hydroxyl groups in uridine protected by hydrophobic <italic toggle="yes">tert</italic>-butyldimethylsilyl groups (TBDMS). The same protecting groups were
used in previously described glycoconjugates that exhibited antiviral
activity.<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>&#8722;<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Structures of the tested glycoconjugates, analogues of
the natural
&#946;4GalT substrate.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c01602_0001.jpg"/></fig><p>The key reaction used
in the synthesis of the proposed glycoconjugate
structures was the copper&#173;(I)-catalyzed 1,3-dipolar azido-alkyne cycloaddition
(CuAAC), which enables the connection of propargyl-containing derivatives
with azide-containing derivatives to form a 1,2,3-triazole ring in
the linker structure.<xref rid="ref22" ref-type="bibr"/> The building blocks <bold>1</bold>&#8211;<bold>13</bold> required for this type of reaction
were previously synthesized in our laboratory, and their synthesis
has been described in earlier works.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref23" ref-type="bibr"/>&#8722;<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref28" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref29" ref-type="bibr"/>
</named-content>
</p><p>CuAAC reactions were performed at room temperature under an
argon
atmosphere to minimize the oxidation of copper&#173;(I) ions generated <italic toggle="yes">in situ</italic> within the reaction mixture. The reactions were
carried out for 24 to 72 h, using an equimolar ratio of reactants
in a THF/<italic toggle="yes">i</italic>-PrOH/H<sub>2</sub>O solvent system. CuSO<sub>4</sub> pentahydrate was used as the source of copper ions, while
sodium ascorbate (NaAsc) served as the reducing agent to convert Cu&#173;(II)
ions to Cu&#173;(I) ions. This method ensured the selective formation of
1,4-disubstituted 1,2,3-triazole derivatives (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>General Procedures for Glycoconjugate
Synthesis<xref rid="s1fn1" ref-type="fn"/>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c01602_0006.jpg"/><p>
<fn id="s1fn1"><label>a</label><p>Reagents and Conditions:
(i)
CuSO<sub>4</sub>&#183;5H<sub>2</sub>O, NaASC, THF/<italic toggle="yes">i</italic>-PrOH, H<sub>2</sub>O, r.t.</p></fn>
</p></fig><p>Glycoconjugates <bold>14</bold> and <bold>15</bold> (Type <bold>I</bold>) served as reference
compounds for comparing the effects
of subsequent structural modifications. In these glycoconjugates,
the sugar is attached <italic toggle="yes">via</italic> an easily enzymatically
hydrolyzed <italic toggle="yes">O</italic>-glycosidic bond, and apart from the
1,2,3-triazole ring, the linker structure does not contain any rigidifying
elements. Glycoconjugates <bold>16</bold> and <bold>17</bold> (Type <bold>II</bold>) feature an amide moiety on the uridine side and a two-carbon
alkyl chain on the sugar side to increase linker flexibility. Additionally,
the 1,2,3-triazole ring was inversed compared to type <bold>I</bold> glycoconjugates. For glycoconjugates <bold>18</bold> and <bold>19</bold> (Type <bold>III)</bold>, an additional amide bond was introduced
into the linker structure to increase its rigidity and enhance its
ability to coordinate metal ions at the GT active center. Moreover,
replacing the anomeric oxygen atom with nitrogen is expected to increase
the resistance to enzymatic hydrolysis by intracellular glycosidases.
To further improve hydrolytic stability, glycoconjugates <bold>20&#8211;25</bold> were synthesized with sulfur replacing oxygen at the anomeric position.
Literature reports indicate that of 1-thiosugar derivatives are used
in treating various human diseases<xref rid="ref30" ref-type="bibr"/> and
that sulfur-containing compounds can effectively complex metal ions.<xref rid="ref31" ref-type="bibr"/> Depending on the combination of sugar derivative <bold>7&#8211;10</bold> and uridine derivative <bold>11&#8211;13</bold>, the glycoconjugates were designed with different orientations of
the 1,2,3-triazole ring (glycoconjugates Type <bold>IV</bold> and <bold>VI</bold>), and varying functional groups&#58872;amide (Type <bold>V</bold>) or ether (Type <bold>VI</bold>) on the side of the junction
with uridine.</p></sec><sec id="sec2.2"><label>2.2</label><title>Biological Evaluation</title><sec id="sec2.2.1"><label>2.2.1</label><title>Anticoronavirus Activity of Uridine Glycoconjugates</title><p>The antiviral activity of the designed compounds was initially
screened against two coronaviruses: murine hepatitis virus strain
A59 (MHV) and human coronavirus strain NL63 (HCoV-NL63). Since MHV
infection in permissive LR7 cells at a multiplicity of infection (MOI)
of 0.01 induces a pronounced cytopathic effect (CPE) 24 h postinfection,
we used a CPE reduction assay to evaluate antiviral activity (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A). Both the protective
efficacy of each compound (50 &#956;M) against MHV infection, and
its cytotoxicity in uninfected cells, was assessed using an MTS-based
proliferation assay. At 50 &#956;M, compounds <bold>14</bold>, <bold>15</bold>, <bold>16</bold>, <bold>17</bold>, <bold>18</bold>, <bold>19</bold>, <bold>23</bold>, <bold>24</bold>, and <bold>25</bold> reduced
cell viability by 10&#8211;30%, while compounds <bold>20</bold>, <bold>21</bold>, and <bold>22</bold> showed no detectable toxicity. The
tested compounds exhibited varying degrees of protection against MHV-induced
CPE. For instance, compounds <bold>18</bold> and <bold>19</bold> (Type <bold>III</bold> glycoconjugates) demonstrated low cytotoxicity but also
limited anti-MHV activity. In contrast, compounds <bold>14</bold>, <bold>15</bold> (Type <bold>I</bold>), <bold>20</bold>, <bold>21</bold> (Type <bold>IV</bold>), <bold>22</bold> (Type <bold>V</bold>), and <bold>24</bold> (Type <bold>VI</bold>) significantly reduced cell death
in MHV-infected LR7 cells. Among these, compounds <bold>20</bold> and <bold>21</bold> were the most effective, nearly eliminating CPE with minimal
compound-induced cytotoxicity.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Analysis of anticoronavirus activity of
compounds <bold>14&#8211;25</bold>. (A) Reduction of MHV cytotoxicity
in LR7 cells following treatment
with 50 &#956;M of each compound. Gray bars indicate cell viability
in the absence of viral infection; black bars indicate cell viability
in MHV-infected LR7 cells. At 1 h postinfection (p.i.), virus-containing
medium (MOI 0.01) was replaced with fresh medium containing 50 &#956;M
of each compound or DMSO. After 24 h, cell viability was measured
via MTS/PMS assay. Results represent the mean of three independent
experiments with error bars showing standard deviations. Statistical
significance was assessed using a <italic toggle="yes">t</italic> test: *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.005, ***<italic toggle="yes">p</italic> &lt; 0.001; ns, not significant. (B) HCoV-NL63 N protein
expression in LLC-Mk2 cells in the presence of 50 &#956;M of each
compound. LLC-Mk2 cells were infected with HCoV-NL63 at an MOI of
0.01. At 2 h p.i., the medium was replaced with a new one supplemented
with 50 &#956;M compound <bold>14&#8211;25</bold> or DMSO. Four
days p.i. the cells were lysed and the expression of N HCoV-NL63 protein
was determined by SDS-PAGE followed by immunoblotting with specific
anti-N antibodies. The level of &#946;-catenin was evaluated as a
loading control. (C) Densitometric analysis of HCoV-NL63 N and &#946;-catenin
protein expression in LLC-Mk2 cells treated with 50 &#956;M of each
compound. The N protein levels were expressed as a percentage relative
to DMSO-treated infected cells, while &#946;-catenin levels were
expressed as a percentage relative to noninfected control cells&#58872;C.
The data are presented as the ratio of N to &#946;-catenin for each
sample, normalized accordingly. Results represent the mean of three
independent experiments, with error bars indicating standard deviations.
Statistical significance of N protein levels in treated infected cells,
compared to DMSO-treated infected cells, was determined using one-way
ANOVA followed by Dunnett&#8217;s posthoc test; *<italic toggle="yes">p</italic> &lt; 0.1, ns &#8211; not significant.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c01602_0002.jpg"/></fig><p>Since HCoV-NL63 infection in LLC-Mk2 cells does
not produce a pronounced
CPE, antiviral activity of the compounds was assessed by analyzing
Nucleocapsid (N) protein levels via Western blot and further densitometry
analysis (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B,C).
No significant reduction in N protein levels was observed in cells
treated with Type II (compounds <bold>16</bold>, <bold>17</bold>),
Type III (compounds <bold>18</bold>, <bold>19</bold>), or Type V (compounds <bold>22</bold>, <bold>23</bold>) glycoconjugates. In contrast, compounds
from Types I (<bold>14</bold>, <bold>15</bold>), IV (<bold>20</bold>, <bold>21</bold>), and VI (<bold>24</bold>, <bold>25</bold>) significantly
reduced the level of N protein production. No N protein was detected
in the presence of compounds <bold>15, 21, 24</bold>, and <bold>25</bold>. Treatment with compound <bold>20</bold> resulted in the reduction
of N, as well as &#946;-catenin levels. Based on their strong antiviral
activity against both MHV and HCoV-NL63 with their acceptable toxicity
profiles, compounds <bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24</bold> were selected for further analysis. Compound <bold>25</bold> was excluded due to lower activity against MHV and high
toxicity, while compound <bold>14</bold> was excluded for its weaker
activity against HCoV-NL63.</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Dose-Dependent
Activity of Selected Uridine
Glycoconjugates against CoVs</title><p>To further evaluate antiviral
activity, the dose-dependent effects of selected compounds against
MHV, HCoV-NL63, and SARS-CoV-2 were examined. The compounds were tested
over a wide range of concentrations by using CPE reduction assays
for MHV and immunoblotting for HCoV-NL63 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A,C). Viral titers in media from infected
cells were also assessed by plaque assay (MHV and SARS-CoV-2) or foci
assay (HCoV-NL63) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B,D,E). All tested compounds showed a dose-dependent reduction
in CPE or in viral titer. Notably, treatment with compounds <bold>20</bold> and <bold>21</bold> at concentrations above 6.25 &#956;M,
and with compounds <bold>15</bold> and <bold>24</bold> at concentrations
above 12.5 &#956;M, significantly reduced MHV-induced CPE in LR7
cells. Compounds <bold>21</bold> and <bold>24</bold> effectively decreased
viral titers, with no detectable virus in cells treated with doses
above 6.25 &#956;M. Against HCoV-NL63, compound <bold>24</bold> showed
the highest antiviral efficacy, completely inhibiting viral protein
expression and viral release at doses above 6.25 &#956;M, while compounds <bold>15</bold>, <bold>20</bold>, and <bold>21</bold> demonstrated slightly
lower activity. Similarly, a dose-dependent antiviral effect was seen
for all of the tested compounds against SARS-CoV-2 (<xref rid="fig3" ref-type="fig">Figure<xref rid="fig3" ref-type="fig"/>
</xref>E).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Antiviral activity of
compounds 15, 20, 21, and 24 on MHV, HCoV-NL63,
and SARS-CoV-2 infection. (A) LR7 cells were infected with MHV (MOI
0.01) and treated with compounds (0&#8211;50 &#956;M) or DMSO. 24
h p.i. PMS/MTS test was performed. The values are presented as a percentage
of the viability of cells treated with DMSO (100%). The gray lines
illustrate the viability analysis of compound-treated noninfected
LR7 cells and MHV-infected cells, respectively. (B) 24 h p.i. the
medium sample was collected and MHV was titrated by a plaque assay.
(C) LLC-Mk2 cells were infected with HCoV-NL63 at an MOI of 0.01 and
treated with compounds (0&#8211;25 &#956;M). Four days p.i. cells
were collected and lysed. Expression of the HCoV-NL63 N protein and,
as a control, &#946;-catenin was evaluated by SDS-PAGE followed by
immunoblotting with specific antibodies. C indicates noninfected LLC-Mk2
cells treated with DMSO for 4 days. (D) The medium sample was collected
and HCoV-NL63 was titrated by a foci-forming assay. (E) Dose-dependent
inhibition of SARS-CoV-2 replication by the compounds <bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24</bold>. Vero cells
were infected with SARS-CoV-2 and 2 h after infection the cells were
treated with different concentrations of the tested molecules. Culture
supernatants were collected at 48 h after infection and analyzed for
SARS-CoV-2 infectivity by plaque assay. Results represent the mean
of three independent experiments with error bars showing standard
deviations. Statistical significance was assessed by <italic toggle="yes">t</italic> test; * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt;
0.005, *** <italic toggle="yes">p</italic> &lt; 0.001, ns &#8211; not significant.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c01602_0003.jpg"/></fig><p>Viral titration assays were used to determine the
half-maximal
inhibitory concentration (IC<sub>50</sub>) for each compound, defined
as the concentration required to reduce the level of virus replication
by 50%. Compounds cytotoxicity in LR7, LLC-Mk2 and Vero cells (0&#8211;100
&#956;M) was evaluated using an MTS-based assay, and the cytotoxic
concentrations (CC<sub>50</sub>) were estimated accordingly. The selectivity
index (SI), calculated as the CC<sub>50</sub>/IC<sub>50</sub> ratio,
provided an indication of each compound&#8217;s therapeutic potential
and safety (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Among the tested compounds, compound <bold>24</bold> showed the
highest SI values against MHV and HCoV-NL63, while compound <bold>20</bold> demonstrated the highest SI against SARS-CoV-2.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Comparison of the Anticoronaviral
Activity (IC<sub>50</sub>) of the Compounds against MHV, HCoV-NL63,
and SARS-CoV-2, along with Their Cytotoxicity (CC<sub>50</sub>) in
LR7, LLC-Mk2, and Vero Cell Lines, and the Corresponding Selectivity
Indexes (SI)<xref rid="t1fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" char="." colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" rowspan="1">
<bold>MHV</bold>
<hr/></th><th colspan="3" align="center" rowspan="1">
<bold>HCoV-NL63</bold>
<hr/></th><th colspan="3" align="center" rowspan="1">
<bold>SARS-CoV-2</bold>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">
<bold>type of uridine glycoconjugate</bold>
</th><th align="center" char="." colspan="1" rowspan="1">
<bold>compound</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>CC</bold>
<sub>
<bold>50</bold>
</sub>
<xref rid="t1fn2" ref-type="table-fn"/>
<bold>[&#956;M]</bold>
</th><th align="center" char="." colspan="1" rowspan="1">
<bold>IC</bold>
<sub>
<bold>50</bold>
</sub>
<xref rid="t1fn3" ref-type="table-fn"/>
<bold>[&#956;M]</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>SI</bold>
<xref rid="t1fn4" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<bold>CC</bold>
<sub>
<bold>50</bold>
</sub>
<bold>[&#956;M]</bold>
</th><th align="center" char="." colspan="1" rowspan="1">
<bold>IC</bold>
<sub>
<bold>50</bold>
</sub>
<bold>[&#956;M]</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>SI</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>CC</bold>
<sub>
<bold>50</bold>
</sub>
<bold>[&#956;M]</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>IC</bold>
<sub>
<bold>50</bold>
</sub>
<bold>[&#956;M]</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>SI</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>I</bold>
</td><td align="char" char="." colspan="1" rowspan="1">
<bold>15</bold>
</td><td align="left" colspan="1" rowspan="1">134.5</td><td align="char" char="." colspan="1" rowspan="1">7.6</td><td align="left" colspan="1" rowspan="1">17.7</td><td align="left" colspan="1" rowspan="1">49.8</td><td align="char" char="." colspan="1" rowspan="1">6.8</td><td align="left" colspan="1" rowspan="1">7.3</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&#8764;27.4</td><td align="left" colspan="1" rowspan="1">&gt;3.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>IV</bold>
</td><td align="char" char="." colspan="1" rowspan="1">
<bold>20</bold>
</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">11.3</td><td align="left" colspan="1" rowspan="1">&gt;8.8</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">5.5</td><td align="left" colspan="1" rowspan="1">&gt;18.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&#8764;16.2</td><td align="left" colspan="1" rowspan="1">&gt;6.2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">
<bold>21</bold>
</td><td align="left" colspan="1" rowspan="1">65.3</td><td align="char" char="." colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">14.5</td><td align="left" colspan="1" rowspan="1">46.7</td><td align="char" char="." colspan="1" rowspan="1">5.7</td><td align="left" colspan="1" rowspan="1">8.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&#8764;19.0</td><td align="left" colspan="1" rowspan="1">&gt;5.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>VI</bold>
</td><td align="char" char="." colspan="1" rowspan="1">
<bold>24</bold>
</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="char" char="." colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">&gt;27.0</td><td align="left" colspan="1" rowspan="1">59.1</td><td align="char" char="." colspan="1" rowspan="1">3.1</td><td align="left" colspan="1" rowspan="1">19.0</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&#8764;18.7</td><td align="left" colspan="1" rowspan="1">&gt;5.3</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Cytotoxicity was measured after
48 h in LR7 and/or 96 h in Vero or LLC-Mk2 cell lines.</p></fn><fn id="t1fn2"><label>b</label><p>the concentration of compound needed
to reduce the cells viability by 50% (CC<sub>50</sub>),</p></fn><fn id="t1fn3"><label>c</label><p>the concentration of compound needed
to reduce the virus titer released from the cells by 50% (IC<sub>50</sub>),</p></fn><fn id="t1fn4"><label>d</label><p>SI&#58872;a CC<sub>50</sub>/IC<sub>50</sub> ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.2.3"><label>2.2.3</label><title>Insights into the Mechanism of Action</title><sec id="sec2.2.3.1"><label>2.2.3.1</label><title>Inhibition
of SARS-CoV-2 Entry</title><p>To investigate whether these compounds
interfere with SARS-CoV-2
entry, a virus-like particle (SC-VLP) system was employed.<xref rid="ref32" ref-type="bibr"/> SC-VLP consists of four SARS-CoV-2 structural
proteins and mRNA carrying a luciferase gene. This system allows for
the evaluation of how alterations in S protein glycosylation affect
particle assembly and entry into permissive cells. Additionally, it
excludes viral RNA replication, isolating potential inhibitory effects
on virus entry. SC-VLPs were produced in the presence of each compound
(3.125&#8211;12.5 &#956;M) or DMSO. The internalization assay demonstrated
a dose-dependent reduction in SC-VLP entry into HEK-hACE2 cells with
all analyzed compounds (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A). Compounds <bold>15</bold> and <bold>21</bold> were particularly
effective, with a 12.5 &#956;M concentration reducing entry by 80%
compared with the control. To determine whether this effect was due
to reduced expression and secretion of S protein, Western blot analysis
was performed on both SC-VLP-producing cells and the corresponding
culture medium using S2-specific antibodies. The analysis revealed
no significant changes in the levels of S2 and N proteins in the producing
cells (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01602/suppl_file/jm5c01602_si_001.pdf" ext-link-type="uri">Supporting Information, S37</ext-link>). However,
some minor alterations in S2 domain levels were observed in the medium
from cells treated with compounds <bold>15</bold>, <bold>20</bold>, and <bold>24</bold>, with a more pronounced reduction detected
in samples treated with compound <bold>21</bold> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B). These findings suggest
that the tested glycoconjugates may alter the glycosylation profile
of the SARS-CoV-2 S protein, thereby inhibiting its interaction with
the ACE2 receptor (compounds <bold>15</bold>, <bold>20</bold>, and <bold>24</bold>) or assembly and secretion of SC-VLP (compound <bold>21</bold>).</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>The effect of uridine glycoconjugates on SC-VLPs entry to HEK-hACE2
cells. (A) HEK293T cells were transfected with SC-VLPs components
and treated with compounds <bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24</bold> (12.5&#8211;3.125 &#956;M). Cell
culture medium was used in the internalization assay using permissive
HEK-hACE2 cell line and HEK293T as a negative control; C&#58872;medium
from nontransfected HEK293T cells. Statistical significance was assessed
using a <italic toggle="yes">t</italic> test: *<italic toggle="yes">p</italic> &lt; 0.05, **<italic toggle="yes">p</italic> &lt; 0.005, ***<italic toggle="yes">p</italic> &lt; 0.001; ns, not
significant. (B) Remaining cell culture medium was subjected to PEG-precipitation,
followed by SDS-PAGE and immunoblotting with S2 domain-specific antibodies.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c01602_0004.jpg"/></fig></sec><sec id="sec2.2.3.2"><label>2.2.3.2</label><title>Inhibition of Coronavirus
Replication</title><p>Our previous studies have shown that uridine
glycoconjugates can
inhibit viral RNA replication, as demonstrated for hepatitis C virus.<xref rid="ref33" ref-type="bibr"/> To evaluate the effect of the selected compounds
on viral RNA synthesis, we analyzed viral RNA levels early in infection
(8 h p.i.) in LR7 cells infected with MHV (MOI of 1) and treated with
increasing concentrations of compounds <bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24</bold> (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A). Low concentrations (3.125&#8211;6.25
&#956;M) of each compound allowed for MHV RNA detection, while higher
concentrations resulted in undetectable viral RNA. Similarly, in HCoV-NL63-infected
LLC-MK2 cells, 12.5 &#956;M of compounds <bold>15</bold>and <bold>21</bold>, as well as 6.25 &#956;M of compounds <bold>20</bold> and <bold>24</bold>, effectively suppressed viral RNA synthesis (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>B).</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Effect of analyzed glycoconjugates
on MHV and HCoV-NL63 RNA synthesis
and SARS-CoV-2 replication. LR7 and LLC-Mk2 cells were infected with
MHV (MOI 1) (A) and HCoV-NL63 (MOI 0.01) (B), respectively. 1 h p.i.
virus-containing medium was removed, and cells were covered with medium
supplemented with different concentrations of analyzed compounds (25&#8211;3.125
&#956;M). 8 h p.i. (MHV) or 96 h (HCoV-NL63) total RNA was isolated.
A fragment of N gene was amplified and analyzed in gel electrophoresis.
As a control for RNA isolation, a fragment of a gene encoding &#946;-actin
was amplified. C&#58872;noninfected cells. Inhibition of SARS-CoV-2
replication. (C) BHK21 cells containing SARS-CoV-2 replicon were seeded
and treated with 25 &#956;M of selected compounds, N (Nirmatrelvir)
as a reference or an equal volume of diluent DMSO for 48 h. Cells
were assayed for luciferase activity using Nano-Glo Luciferase Assay
System (Promega). Results were presented as a percentage of luminescence
signal from compound-treated cells relative to cells treated with
DMSO only. Dunnett&#8217;s One-way ANOVA test was used for statistical
analysis. The statistical significance of relativity to DMSO is represented
as follows: ns <italic toggle="yes">p</italic> &gt; 0.05, ** <italic toggle="yes">p</italic> &lt;
0.01, *** <italic toggle="yes">p</italic> &lt; 0.001. Error bars stand for standard
deviation between three biological repeats, three technical replicates
each.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c01602_0005.jpg"/></fig><p>Additionally, the SARS-CoV-2 replicon
system in the BHK-21 cell
line was used to evaluate the effect of the analyzed compounds on
viral replication process, in comparison with nirmatrelvir, a known
3C-like protease inhibitor that blocks virus replication.<xref rid="ref34" ref-type="bibr"/> Treatment of replicon-containing cells with
25 &#956;M compounds <bold>20</bold> and <bold>24</bold>, as well
as nirmatrelvir, inhibited SARS-CoV-2 replication (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>C).</p><p>Together, these results
support the antiviral potential of uridine
glycoconjugates and suggest that the inhibition of viral RNA synthesis
may be one of their potential mechanisms of action against coronaviruses.</p><p>The presented data indicate that the analyzed uridine glycoconjugates
(compounds <bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24</bold>) exhibit antiviral properties against coronaviruses. While
all of the compounds inhibited the replication of model coronaviruses,
only compounds <bold>20</bold> and <bold>24</bold> effectively suppressed
SARS-CoV-2 replication. Additionally, all tested compounds altered
the entry of SARS-CoV-2 VLPs into permissive cells. Therefore, these
findings suggest that compounds <bold>20</bold> and <bold>24</bold> may have a dual mechanism of action, involving both the alteration
of viral protein glycosylation and the inhibition of RNA replication.
However, further studies are needed to confirm and clarify these mechanisms
in detail.</p></sec></sec></sec></sec><sec id="sec3"><label>3</label><title>Discussion and Conclusions</title><p>Envelope
glycoproteins, such as the spike protein in coronaviruses,
are essential for the viral life cycle. They play a key role in viral
assembly and entry by interacting with host cell receptors and initiating
fusion with host cell membranes. Since glycosylation seems to be essential
for multiple stages of the coronavirus replication cycle, targeting
the glycosylation maturation process represents a promising strategy
for the development of anticoronavirus drugs.</p><p>In murine hepatitis
virus (MHV), for example, tunicamycin treatment
disrupts the incorporation of the spike glycoprotein into virions,
significantly reducing viral titers.<xref rid="ref35" ref-type="bibr"/> Similar
experiments with various glycosylation inhibitors have confirmed the
importance of <italic toggle="yes">N</italic>-glycosylation for the production
and infectivity of SARS-CoV-2 virions.<xref rid="ref36" ref-type="bibr"/> Moreover, studies by Gadlage<xref rid="ref37" ref-type="bibr"/> suggested
that <italic toggle="yes">N</italic>-glycosylation of the MHV-encoded nsp4 protein
is crucial for efficient double membrane vesicle (DMV) formation,
which is essential for RNA synthesis. Consequently, it is not surprising
that inhibition or alterations of the glycosylation process in viral
proteins often leads to antiviral effects.<xref rid="ref38" ref-type="bibr"/>
</p><p>The aim of this study was to evaluate the effect of a series
of
uridine glycoconjugates as potential glycosyltransferase (GT) inhibitors
on the coronavirus life cycle. These compounds were designed to resemble
GT donor substrates, incorporating structural modifications such as
a 1,2,3-triazole ring and hydrophobic protecting groups, to enhance
their stability and antiviral activity. Our previous studies on the <italic toggle="yes">Flaviviridae</italic> viruses highlighted the antiviral potential
of similar glycoconjugates, particularly those containing 1,2,3-triazole
linkers and TBDMS-protected uridine.<xref rid="ref19" ref-type="bibr"/> In
this study, we found that both the presence of various heteroatoms
strongly influenced antiviral activity in the anomeric position of
the sugar and the type of bond in the linker structure. Specifically,
uridine glycoconjugates with an ether linkage and oxygen as the anomeric
heteroatom exhibited anticoronavirus activity, while amide-linked
glycoconjugates showed either no activity or high cytotoxicity (Types <bold>II</bold>, <bold>III</bold>, and <bold>V</bold>). Notably, glycoconjugates
with sulfur at the anomeric position (Types <bold>IV</bold> and <bold>VI</bold>) were particularly effective, with compound <bold>24</bold> (a <sc>d</sc>-glucose derivative) displaying the highest potency
against both MHV and HCoV-NL63. For most of the glycoconjugate types
(except Type <bold>II</bold>), the <sc>d</sc>-glucose derivative demonstrated
slightly higher activity than the <sc>d</sc>-galactose derivative.
However, for glycoconjugates of type <bold>VI</bold>, this difference
in activity was notably greater. Considering both the cytotoxicity
of the compounds and their antiviral activity against MHV and/or HCoV-NL63,
we selected four compounds (<bold>15</bold>, <bold>20</bold>, <bold>21</bold>, and <bold>24)</bold> as the most promising candidates
based on preliminary screening. Compound <bold>24</bold> exhibited
the lowest IC<sub>50</sub> values (3.70 &#956;M for MHV and 3.10
&#956;M for HCoV-NL63) along with high selectivity indexes of 26.96
and 19.05 for MHV and HCoV-NL63, respectively. All four selected compounds
also demonstrated anti-SARS-CoV-2 activity in Vero cells, though with
reduced potency. At a concentration of 25 &#956;M, approximately
60&#8211;90% reduction in viral titers was observed, with compound <bold>20</bold> showing the highest level of activity. However, it should
be mentioned that some inhibition of the replication cycle during
the titration of coronaviruses or SC-VLP internalization may be attributed
to the residual amount of compounds in the medium samples.</p><p>Using
the SARS-CoV-2 VLP system, we confirmed that the selected
compounds can interfere with VLP assembly or their interaction with
hACE2 receptors in HEK293 cells, as shown by the internalization assay.
These results support the hypothesis that the compounds exert glycosyltransferase
(GT) inhibitory activity. However, the observed differences in compound
activity between the authentic virus and the SC-VLP system may result
from variations in the expression of GTs across different cell lines
or differences in the glycosylation profile. Additionally, our compounds
were designed as analogues of &#946;-1, 4-galactosyltransferase substrate,
a family of enzymes localized in the Golgi apparatus.</p><p>Recent
studies have also suggested that targeting &#945;-glucosidases
(e.g., with miglustat, celgosivir) in the early steps in the glycosylation
pathway may be more effective at blocking SARS-CoV-2 infection in
various cell types than inhibiting downstream Golgi &#945;-mannosidases
I and II or &#945;-galactosidases.<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> Moreover, additional analysis of coronavirus RNA
synthesis in infected cells and SARS-CoV-2 replication using the replicon
system suggests that the compounds may also impair viral replication.
However, replication inhibition was observed for only two compounds
(<bold>20</bold> and <bold>24</bold>), and this effect was partial,
suggesting that the compounds may affect replication indirectly.</p><p>Since our compounds target glycosyltransferases (GTs), cytotoxicity
is a significant concern. While these compounds may interfere with
host glycosylation, their impact likely depends on the structure of
the specific glycoprotein and the type of host cell. The SARS-CoV-2
S protein is highly glycosylated with certain glycan types and patterns
that are preferentially utilized by the virus. Due to its tightly
lattice structure, even minor conformational changes in glycan composition
may be poorly tolerated, potentially contributing to the greater selectivity
of the compounds toward viral proteins. In contrast, many host glycoproteins
can tolerate glycosylation inhibition (e.g., glucosidase inhibition)
without a significant loss of function, as proper folding does not
always rely exclusively on the calnexin/calreticulin system. It has
also been demonstrated that the rapid synthesis of viral glycoproteins
during acute infection makes enveloped viruses more susceptible to
ER &#945;-glucosidase inhibition than host cells.<xref rid="ref41" ref-type="bibr"/>
</p><p>It should be underlined that some inhibitors targeting
enzymes
from the glycosidase group, which act at early stages of the glycosylation
process, have been tested in clinical trials. Nonetheless, &#945;-glucosidase
inhibitors&#58872;such as celgosivir (investigated for HCV treatment)
and miglustat (NB-DNJ)&#58872;have been associated with adverse effects
in humans, including diarrhea, weight loss, and flatulence.<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref43" ref-type="bibr"/>
</named-content> Inhibitors targeting a broad spectrum of glycosidases may disrupt
not only the post-translational modification of host proteins but
also carbohydrate metabolism, thereby affecting physiological processes.</p><p>Despite these findings, the selectivity of GT inhibitors has remained
poorly characterized. Further research is needed to elucidate their
specific inhibitory effects on various glycosidases and glycosyltransferases,
which could support the development of novel, more selective antiviral
agents.</p><p>The primary aim of this work was to provide a proof-of-concept
demonstration that the tested compounds have the potential to interfere
with the replication cycle of coronaviruses. Our results show consistent
antiviral effects in relevant <italic toggle="yes">in vitro</italic> models, which
supports the hypothesis that interference with host glycosylation
pathways may impair viral replication. Given the well-documented role
of host glycosylation machinery&#58872;particularly in the processing
of viral glycoproteins, it is plausible that the observed antiviral
effects are at least partially on-target. Therefore, our findings
may indicate a potential dual mechanism of action for the tested uridine
glycoconjugates: inhibition of GTs and disruption of RNA replication.
Further studies are needed to clarify the exact mechanism of action
and selectivity toward coronavirus proteins.</p></sec><sec id="sec4"><label>4</label><title>Experimental Section</title><sec id="sec4.1"><label>4.1</label><title>General
Information</title><p>The structures
and purity of all glycoconjugates were confirmed using NMR and HPLC/MS/MS
methods (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01602/suppl_file/jm5c01602_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>). All compounds
are &gt;95% pure by HPLC analysis. Nuclear magnetic resonance (<sup>1</sup>H NMR and <sup>13</sup>C NMR) spectra were determined in CDCl<sub>3</sub>, using TMS as an internal standard, and recorded with an
Agilent spectrometer at a frequency of 400 MHz or with a Varian spectrometer
at a frequency of 600 MHz. NMR solvents were purchased from ACROS
Organics (Geel, Belgium) or Deutero GmbH (Kastellaun, Germany). Chemical
shifts (&#948;) are given in parts per million (ppm), and coupling
constants (<italic toggle="yes">J</italic>) are given in Hz. Splitting patterns
are designated as follows: s, singlet; d, doublet; dd, doublet of
doublets; t, triplet; dd &#8764; t, doublet of doublets resembling
a triplet; ddd, doublet of doublet of doublets; m, multiplet; bs,
broad singlet. Optical rotations were measured using a JASCO P-2000
polarimeter equipped with a sodium lamp (589.3 nm) at room temperature.
Melting points were determined using an OptiMelt (MPA 100) from Stanford
Research Systems. Mass spectra were recorded with a WATERS LCT Premier
XE LC/MS system (high-resolution mass spectrometer equipped with an
electron spray ionization source and a high-resolution orthogonal
TOF analyzer). Reactions were monitored by thin-layer chromatography
(TLC) on precoated plates of silica gel 60 F254 (Merck KGaA, Darmstadt,
Germany). TLC plates were inspected under UV light (&#955; = 254
nm) or charring after spraying with 10% ethanolic solution of sulfuric
acid. All products were purified using column chromatography performed
on Silica Gel 60 (70&#8211;230 mesh, Merck KGaA, Darmstadt, Germany)
developed with hexane/EtOAc, toluene/EtOAc, or CHCl<sub>3</sub>/MeOH
solvent systems in various volume ratios. All evaporations were performed
under a diminished pressure at 45 &#176;C on a rotary evaporator.</p><p>Sugars (<sc>d</sc>-glucose and <sc>d</sc>-galactose), uridine, other
chemicals, and solvents were purchased from Sigma-Aldrich (Steinheim,
Germany), ACROS Organics (Geel, Belgium) or Avantor (Gliwice, Poland)
and were used without purification. Propargyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-glucopyranoside (<bold>1</bold>), propargyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-galactopyranoside (<bold>2</bold>),<xref rid="ref26" ref-type="bibr"/> 2-azidoethyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-glucopyranoside (<bold>3</bold>),<xref rid="ref25" ref-type="bibr"/> 2-azidoethyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-galactopyranoside (<bold>4</bold>),<xref rid="ref27" ref-type="bibr"/>
<italic toggle="yes">N</italic>-(2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-glucopyranosyl)&#173;azidoacetamide (<bold>5</bold>), <italic toggle="yes">N</italic>-(2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-&#946;-<sc>d</sc>-galactopyranosyl)&#173;azidoacetamide
(<bold>6</bold>),<xref rid="ref24" ref-type="bibr"/> propargyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-1-thio-&#946;-<sc>d</sc>-glucopyranoside (<bold>7</bold>), propargyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-1-thio-&#946;-<sc>d</sc>-galactopyranoside (<bold>8</bold>),<xref rid="ref28" ref-type="bibr"/> azidomethyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-1-thio-&#946;-<sc>d</sc>-glucopyranoside (<bold>9</bold>), azidomethyl 2,3,4,6-tetra-<italic toggle="yes">O</italic>-acetyl-1-thio-&#946;-<sc>d</sc>-galactopyranoside (<bold>10</bold>),<xref rid="ref29" ref-type="bibr"/> 5&#8242;-azido-5&#8242;-deoxy-2&#8242;,3&#8242;-di-<italic toggle="yes">O</italic>-<italic toggle="yes">tert</italic>-butyldimethylsilyl-uridine (<bold>11</bold>),<xref rid="ref23" ref-type="bibr"/>
<italic toggle="yes">N</italic>-propargyl-2&#8242;,3&#8242;di-<italic toggle="yes">O-tert</italic>-butyldimethylsilyluridine-5&#8242;-amide (<bold>12</bold>), 2&#8242;,3&#8242;di-<italic toggle="yes">O</italic>-<italic toggle="yes">tert</italic>-butyldimethylsilyl-5&#8242;-<italic toggle="yes">O</italic>-propargyl-uridine
(<bold>13</bold>)<xref rid="ref19" ref-type="bibr"/> were prepared according
to the respective published procedures.</p><sec id="sec4.1.1"><label>4.1.1</label><title>General
Procedure for the Synthesis of Glycoconjugates
by CuAAC Reaction</title><p>To a solutions of a suitably functionalized <italic toggle="yes">O</italic>-acetylated sugar derivatives <bold>1</bold>&#8211;<bold>10</bold> (0.2 mmol) and uridine derivatives <bold>11</bold>&#8211;<bold>13</bold> (0.2 mmol) in THF (2 mL) and <italic toggle="yes">i</italic>-PrOH (2
mL) mixture, CuSO<sub>4</sub>&#183;5H<sub>2</sub>O (10 mg, 0.04 mmol)
dissolved in H<sub>2</sub>O (1 mL) was added immediately after mixing
it with sodium ascorbate aqueous solution (16 mg, 0.08 mmol in 1 mL
of water). The reaction mixtures thus obtained were stirred for 24&#8211;72
h at r.t. The progress of the reaction was monitored on TLC (CHCl<sub>3</sub>:CH<sub>3</sub>OH 20:1 or toluene: ethyl acetate 1:1 solvents
system). After completion, the reaction mixtures were concentrated <italic toggle="yes">in vacuo</italic> and purified using column chromatography to give
products <bold>14</bold>&#8211;<bold>25</bold>.</p><sec id="sec4.1.1.1"><label>4.1.1.1</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-deoxy-5&#8242;-[4-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-glucopyranosyloxymethyl)-1,2-3-triazol-1-yl]&#173;uridine (<bold>14</bold>)</title><p>The crude product was purified by column chromatography
(toluene:ethyl acetate gradient from 8:1 to 1:1) to give <bold>14</bold> (162 mg, 92%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;4.8 (<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 100&#8211;109
&#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) &#948;: 0.02,
0.08, 0.11, 0.12 (4s, 12H, CH<sub>3</sub>Si), 0.88, 0.92 (2s, 18H,
(CH<sub>3</sub>)<sub>3</sub>C), 2.01, 2.02, 2.03, 2.09 (4s, 12H, CH<sub>3</sub>CO), 3.74 (ddd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 10.0 Hz, H-5<sub>glu</sub>), 4.4
(dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 4.1 Hz, <italic toggle="yes">J</italic> = 4.1 Hz, H-3&#8242;<sub>ur</sub>), 4.19 (dd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 12.3 Hz, H-6a<sub>glu</sub>), 4.26
(dd, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 12.3 Hz,
H-6b<sub>glu</sub>), 4.32 (m, 1H, H-4&#8242;<sub>ur</sub>), 4.57&#8211;4.68
(m, 4H, H-2&#8242;<sub>ur</sub>, H-1<sub>glu</sub>, H-5&#8242;a<sub>ur</sub>, H-5&#8242;b<sub>ur</sub>), 4.79 and 4.96 (qAB, 2H, <italic toggle="yes">J</italic> = 12.6 Hz, CH<sub>2</sub>), 5.04 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 7.9 Hz, <italic toggle="yes">J</italic> = 9.7 Hz, H-2<sub>glu</sub>), 5.11 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.0 Hz, H-4<sub>glu</sub>), 5.21 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.7 Hz, H-3<sub>glu</sub>), 5.39 (d, 1H, <italic toggle="yes">J</italic> = 5.3 Hz, H-1&#8242;<sub>ur</sub>), 5.72 (dd, 1H, <italic toggle="yes">J</italic> = 2.3 Hz, <italic toggle="yes">J</italic> =
8.2 Hz, H-5<sub>ur</sub>), 6.98 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz,
H-6<sub>ur</sub>), 7.63 (s, 1H, H-5<sub>triaz</sub>), 8.66 (s, 1H,
NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) &#948;: &#8722;4.79,
&#8722;4.73, &#8722;4.57, &#8722;4.36 (<underline>C</underline>H<sub>3</sub>Si), 17.92, 18.02 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.60, 20.68, 20.75, 21.44 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.73, 25.77 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 51.22 (C-5&#8242;<sub>ur</sub>), 61.80, 63.34 (C-6<sub>glu</sub>, CH<sub>2</sub>O), 68.32, 71.21, 71.96, 72.35, 72.65, 72.93
(C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>), 83.06 (C-4&#8242;<sub>ur</sub>), 94.97 (C-1&#8242;<sub>ur</sub>), 100.24 (C-1<sub>glu</sub>), 102.63 (C-5<sub>ur</sub>), 124.48 (C-5<sub>triaz</sub>), 142.70,
144.28 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 149.77 (C-2<sub>ur</sub>), 162.49 (C-4<sub>ur</sub>), 169.39, 170.25, 170.74 (CO). ESI-HRMS:
calcd for C<sub>38</sub>H<sub>61</sub>N<sub>5</sub>O<sub>15</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 906.3600. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 906.3624.</p></sec><sec id="sec4.1.1.2"><label>4.1.1.2</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-deoxy-5&#8242;-[4-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-galactopyranosyloxymethyl)-1,2-3-triazol-1-yl]&#173;uridine (<bold>15</bold>)</title><p>The crude product was purified by column chromatography
(toluene:ethyl acetate gradient from 8:1 to 1:1) to give <bold>15</bold> (135 mg, 77%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;1.2 (<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 105&#8211;108
&#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: 0.02,
0.08, 0.12, 0.13 (4s, 12H, CH<sub>3</sub>Si), 0.88, 0.93 (2s, 18H,
(CH<sub>3</sub>)<sub>3</sub>C), 1.99, 2.03, 2.06, 2.16 (4s, 12H, CH<sub>3</sub>CO), 3.95 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 6.7 Hz, <italic toggle="yes">J</italic> = 6.7 Hz, H-5<sub>gal</sub>), 4.08&#8211;4.17 (m, 2H,
H-6a<sub>gal</sub>, H-3&#8242;<sub>ur</sub>), 4.21 (dd, 1H, <italic toggle="yes">J</italic> = 6.7 Hz, <italic toggle="yes">J</italic> = 11.3 Hz, H-6b<sub>gal</sub>), 4.31 (m, 1H, H-4&#8242;<sub>ur</sub>), 4.56&#8211;4.69 (m, 4H,
H-2&#8242;<sub>ur</sub>, H-1<sub>gal</sub>, H-5&#8242;a<sub>ur</sub>, H-5&#8242;b<sub>ur</sub>), 4.77 and 4.99 (qAB, 2H, <italic toggle="yes">J</italic> = 12.5 Hz, CH<sub>2</sub>), 5.03 (dd, 1H, <italic toggle="yes">J</italic> = 3.1
Hz, <italic toggle="yes">J</italic> = 10.6 Hz, H-3<sub>gal</sub>), 5.24 (dd, 1H, <italic toggle="yes">J</italic> = 7.8 Hz, <italic toggle="yes">J</italic> = 10.6 Hz, H-2<sub>gal</sub>), 5.37 (d, 1H, <italic toggle="yes">J</italic> = 5.5 Hz, H-1&#8242;<sub>ur</sub>), 5.40 (d, 1H, <italic toggle="yes">J</italic> = 3.1 Hz, H-4<sub>gal</sub>),
5.72 (dd, 1H, <italic toggle="yes">J</italic> = 2.0 Hz, <italic toggle="yes">J</italic> = 8.0
Hz, H-5<sub>ur</sub>), 6.97 (d, 1H, <italic toggle="yes">J</italic> = 8.0 Hz, H-6<sub>ur</sub>), 7.63 (s, 1H, H-5<sub>triaz</sub>), 8.65 (s, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;4.78,
&#8722;4.68, &#8722;4.52, &#8722;4.35 (<underline>C</underline>H<sub>3</sub>Si), 17.94, 18.05 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.69, 20.83 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.75, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 51.20 (C-5&#8242;<sub>ur</sub>), 61.26, 63.52 (C-6<sub>gal</sub>, CH<sub>2</sub>O), 67.02, 68.87, 70.77, 72.23, 72.97 (C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>gal</sub>, C-4<sub>gal</sub>), 83.18 (C-4&#8242;<sub>ur</sub>), 95.09 (C-1&#8242;<sub>ur</sub>), 100.90 (C-1<sub>gal</sub>),
102.63 (C-5<sub>ur</sub>), 124.45 (C-5<sub>triaz</sub>), 142.87, 144.38
(C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 149.81 (C-2<sub>ur</sub>),
162.51 (C-4<sub>ur</sub>), 169.78, 170.13, 170.26, 170.46 (CO). ESI-HRMS:
calcd for C<sub>38</sub>H<sub>61</sub>N<sub>5</sub>O<sub>15</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 906.3600. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 906.3611.</p></sec><sec id="sec4.1.1.3"><label>4.1.1.3</label><title>
<italic toggle="yes">N</italic>-Uracil [(1-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-glucopyranosyloxyethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>16</bold>)</title><p>The crude product was purified by column
chromatography (first toluene:ethyl acetate gradient from 4:1 to 1:1
and next CHCl<sub>3</sub>:MeOH, gradient from 100:1 to 80:1) to give <bold>16</bold> (112 mg, 60%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;18.0
(<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 106&#8211;109 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400
MHz) &#948;: &#8722;0.03, 0.04, 0.12, 0.18 (4s, 12H, CH<sub>3</sub>Si), 0.85, 0.93 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 1.98, 2.01,
2.02, 2.09 (4s, 12H, CH<sub>3</sub>CO), 3.70 (ddd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 9.8
Hz, H-5<sub>glu</sub>), 3.93 (m, 1H, CH), 4.13 (dd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 12.5 Hz, H-6a<sub>glu</sub>), 4.25
(dd, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 12.5 Hz,
H-6b<sub>glu</sub>), 4.32 (dd, 1H, <italic toggle="yes">J</italic> = 1.2 Hz, <italic toggle="yes">J</italic> = 4.3 Hz, H-3&#8242;<sub>ur</sub>), 4.40 (d, 1H, <italic toggle="yes">J</italic> = 1.2 Hz, H-4&#8242;<sub>ur</sub>), 4.48 (d, 1H, <italic toggle="yes">J</italic> = 7.8 Hz, H-1<sub>glu</sub>), 4.49&#8211;4.67 (m, 5H,4
&#215; CH, H-2&#8242;<sub>ur</sub>), 5.00 (dd, 1H, <italic toggle="yes">J</italic> = 7.8 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-2<sub>glu</sub>), 5.06
(dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-4<sub>glu</sub>), 5.19 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-3<sub>glu</sub>), 5.51
(d, 1H, <italic toggle="yes">J</italic> = 7.4 Hz, H-1&#8242;<sub>ur</sub>), 5.78
(dd, 1H, <italic toggle="yes">J</italic> = 2.2 Hz, <italic toggle="yes">J</italic> = 8.0 Hz,
H-5<sub>ur</sub>), 7.55 (d, 1H, <italic toggle="yes">J</italic> = 8.0 Hz, H-6<sub>ur</sub>), 7.58 (s, 1H, H-5<sub>triaz</sub>), 7.94 (dd &#8764; t,
1H, <italic toggle="yes">J</italic> = 5.5 Hz, <italic toggle="yes">J</italic> = 5.5 Hz, N<underline>H</underline>CH<sub>2</sub>), 8.58 (m, 1H, NH). <sup>13</sup>C NMR
(CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;5.11, &#8722;4.69, &#8722;4.49
(<underline>C</underline>H<sub>3</sub>Si), 17.89, 18.04 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.58, 20.74 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.69, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 34.89 (CH<sub>2</sub>), 50.09 (CH<sub>2</sub>N), 61.76, 67.74 (C-6<sub>glu</sub>, CH<sub>2</sub>O), 68.27,
71.07, 71.22, 72.04, 72.35, 74.80 (C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>), 85.34 (C-4&#8242;<sub>ur</sub>), 94.07 (C-1&#8242;<sub>ur</sub>), 100.52 (C-1<sub>glu</sub>), 102.91 (C-5<sub>ur</sub>),
123.18 (C-5<sub>triaz</sub>), 143.85, 144.16 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.42 (C-2<sub>ur</sub>), 162.30 (C-4<sub>ur</sub>), 169.24, 169.38, 169.86, 170.13, 170.65 (CO). ESI-HRMS: calcd for
C<sub>40</sub>H<sub>64</sub>N<sub>6</sub>O<sub>16</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 963.3815.
Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 963.3805.</p></sec><sec id="sec4.1.1.4"><label>4.1.1.4</label><title>
<italic toggle="yes">N</italic>-Uracil [(1-(2&#8243;,
3&#8243;, 4&#8243;, 6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-galactopyranosyloxyethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>17</bold>)</title><p>The crude product was purified by column
chromatography (first toluene:ethyl acetate gradient from 4:1 to 1:1
and next CHCl<sub>3</sub>:MeOH, gradient from 100:1 to 80:1) to give <bold>17</bold> (153 mg, 81%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;17.6
(<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 116&#8211;120 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400
MHz) &#948;: 0.03, 0.04, 0.12, 0.17 (4s, 12H, CH<sub>3</sub>Si),
0.84, 0.93 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 1.99, 2.05, 2.06,
2.17 (4s, 12H, CH<sub>3</sub>CO), 3.89&#8211;3.96 (m, 2H, CH, H-5<sub>gal</sub>), 4.11 (dd, 1H, <italic toggle="yes">J</italic> = 6.7 Hz, <italic toggle="yes">J</italic> = 11.3 Hz, H-6a<sub>gal</sub>), 4.17 (dd, 1H, <italic toggle="yes">J</italic> = 6.7 Hz, <italic toggle="yes">J</italic> = 11.3 Hz, H-6b<sub>gal</sub>), 4.25
(m, 1H, CH), 4.32 (dd, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 4.3 Hz, H-3&#8242;<sub>ur</sub>), 4.41 (d, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, H-4&#8242;<sub>ur</sub>), 4.45 (d, 1H, <italic toggle="yes">J</italic> = 7.8 Hz, H-1<sub>gal</sub>), 4.46&#8211;4.67 (m, 5H, 5 &#215;
CH, H-2&#8242;<sub>ur</sub>)<sub>,</sub> 5.00 (dd, 1H, <italic toggle="yes">J</italic> = 3.5 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-3<sub>gal</sub>), 5.18
(dd, 1H, <italic toggle="yes">J</italic> = 7.8 Hz, <italic toggle="yes">J</italic> = 10.2 Hz,
H-2<sub>gal</sub>), 5.40 (dd, 1H, <italic toggle="yes">J</italic> = 0.8 Hz, <italic toggle="yes">J</italic> = 3.5 Hz, H-4<sub>gal</sub>), 5.54 (d, 1H, <italic toggle="yes">J</italic> = 7.4 Hz, H-1&#8242;<sub>ur</sub>), 5.79 (dd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 7.59 (d,
1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 7.59 (s, 1H, H-5<sub>triaz</sub>), 7.88 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 5.5 Hz, <italic toggle="yes">J</italic> = 5.5 Hz, N<underline>H</underline>CH<sub>2</sub>), 8.81
(s, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;:
&#8722;5.09, &#8722;4.71, &#8722;4.68, &#8722;4.50 (<underline>C</underline>H<sub>3</sub>Si), 17.89, 18.04 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.56, 20.64, 20.66, 20.68 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.70, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 34.94 (CH<sub>2</sub>), 50.10 (CH<sub>2</sub>N), 61.17, 66.87 (C-6<sub>gal</sub>, CH<sub>2</sub>O), 67.59,
68.68, 70.52, 70.97, 71.39, 74.79 (C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>gal</sub>, C-4<sub>gal</sub>), 85.26 (C-4&#8242;<sub>ur</sub>), 93.83 (C-1&#8242;<sub>ur</sub>), 100.95 (C-1<sub>gal</sub>), 102.90 (C-5<sub>ur</sub>),
123.26 (C-5<sub>triaz</sub>), 143.75, 144.07 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.49 (C-2<sub>ur</sub>), 162.50 (C-4<sub>ur</sub>), 169.28, 170.02, 170.07, 170.13, 170.40 (CO). ESI-HRMS: calcd for
C<sub>40</sub>H<sub>64</sub>N<sub>6</sub>O<sub>16</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 963.3815.
Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 963.3811.</p></sec><sec id="sec4.1.1.5"><label>4.1.1.5</label><title>
<italic toggle="yes">N</italic>-Uracil [((1-(2-oxo-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-glucopyranosyl)&#173;amino)&#173;ethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>18</bold>)</title><p>The crude product was purified by column
chromatography (CHCl<sub>3</sub>:MeOH, gradient from 100:1 to 80:1)
to give <bold>18</bold> (126 mg, 66%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;12.0 (<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 141&#8211;143 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: &#8722;0.04, 0.05, 0.13, 0.20 (4s, 12H,
CH<sub>3</sub>Si), 0.85, 0.94 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 2.00, 2.01, 2.03, 2.07 (4s, 12H, CH<sub>3</sub>CO), 4.01 (ddd,
1H, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 4.1 Hz, <italic toggle="yes">J</italic> = 10.28 Hz, H-5<sub>glu</sub>), 4.07 (dd, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 12.5 Hz, H-6a<sub>glu</sub>), 4.31 (dd, 1H, <italic toggle="yes">J</italic> = 4.1 Hz, <italic toggle="yes">J</italic> =
12.5 Hz, H-6b<sub>glu</sub>), 4.35 (d, 1H, <italic toggle="yes">J</italic> = 4.7
Hz, H-3&#8242;<sub>ur</sub>), 4.39 (bs, 1H, H-4&#8242;<sub>ur</sub>), 4.53&#8211;4.68 (m, 2H, CH<sub>2</sub>), 4.87 (dd, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 8.0 Hz, H-2&#8242;<sub>ur</sub>), 4.91 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-4<sub>glu</sub>), 4.98 and 5.18 (qAB, 2H, <italic toggle="yes">J</italic> = 7.8 Hz, CH<sub>2</sub>), 5.08 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-2<sub>glu</sub>), 5.27&#8211;5.38 (m, 3H, H-1&#8242;<sub>ur</sub>, H-1<sub>glu</sub>, H-3<sub>glu</sub>), 5.75 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 7.08 (d, 1H, <italic toggle="yes">J</italic> = 8.6 Hz, NH), 7.31 (d,
1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 7.86 (m, 1H, NH),
7.92 (s, 1H, H-5<sub>triaz</sub>), 9.17 (s, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;5.06, &#8722;4.69,
&#8722;4.67, &#8722;4.45 (<underline>C</underline>H<sub>3</sub>Si),
17.88, 18.04 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.56, 20.58, 20.62, 20.74 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.71, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 35.46 (CH<sub>2</sub>NH), 52.48 (N<underline>C</underline>H<sub>2</sub>CO), 61.50 (C-6<sub>glu</sub>), 67.90, 70.21, 70.67, 72.44,
73.67, 74.82 (C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>), 78.55 (C-1<sub>glu</sub>), 85.76 (C-4&#8242;<sub>ur</sub>), 96.07
(C-1&#8242;<sub>ur</sub>), 102.90 (C-5<sub>ur</sub>), 124.58 (C-5<sub>triaz</sub>), 144.29, 144.73 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.48 (C-2<sub>ur</sub>), 162.60 (C-4<sub>ur</sub>), 166.04,
169.14 (CONH), 169.58, 169.74, 170.55, 171.46 (CO). ESI-HRMS: calcd
for C<sub>40</sub>H<sub>63</sub>N<sub>7</sub>O<sub>16</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 976.3768. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 976.3769.</p></sec><sec id="sec4.1.1.6"><label>4.1.1.6</label><title>
<italic toggle="yes">N</italic>-Uracil [((1-(2-oxo-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-galactopyranosyl)&#173;amino)&#173;ethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>19</bold>)</title><p>The crude product was purified by column
chromatography (CHCl<sub>3</sub>:MeOH, gradient from 100:1 to 60:1)
to give <bold>19</bold> (130 mg, 68%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;3.8 (<italic toggle="yes">c</italic> = 1.0, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 135&#8211;137 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: &#8722;0.04, 0.05, 0.13, 0.19 (4s, 12H,
CH<sub>3</sub>Si), 0.85, 0.94 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 1.98, 2.01, 2.03, 2.14 (4s, 12H, CH<sub>3</sub>CO), 4.04&#8211;4.21
(m, 3H, H-5<sub>gal</sub>, H-6a<sub>gal</sub>, H-6b<sub>gal</sub>),
4.34 (d, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, H-3&#8242;<sub>ur</sub>), 4.39 (s, 1H, H-4&#8242;<sub>ur</sub>), 4.54&#8211;4.68 (m, 2H,
CH<sub>2</sub>), 4.84 (dd, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 7.6 Hz, H-2&#8242;<sub>ur</sub>), 4.98 and 5.17 (qAB,
2H, <italic toggle="yes">J</italic> = 16.0 Hz, CH<sub>2</sub>), 5.07 (1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-2<sub>gal</sub>), 5.18 (dd, 1H, <italic toggle="yes">J</italic> = 3.5 Hz, <italic toggle="yes">J</italic> =
10.2 Hz, H-3<sub>gal</sub>), 5.30 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.0 Hz, <italic toggle="yes">J</italic> = 9.0 Hz, H-1<sub>gal</sub>), 5.32
(d, 1H, <italic toggle="yes">J</italic> = 7.6 Hz, H-1&#8242;<sub>ur</sub>), 5.45
(d, 1H, <italic toggle="yes">J</italic> = 3.5 Hz, H-4<sub>gal</sub>), 5.75 (d,
1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 7.01 (d, 1H, <italic toggle="yes">J</italic> = 8.6 Hz, NH), 7.34 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz,
H-6<sub>ur</sub>), 7.87 (m, 1H, NH), 7.90 (s, 1H, H-5<sub>triaz</sub>), 9.17 (s, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)
&#948;: &#8722;5.05, &#8722;4.69, &#8722;4.45 (<underline>C</underline>H<sub>3</sub>Si), 17.88, 18.04 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.52, 20.60, 20.68 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.71, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 35.40 (CH<sub>2</sub>NH), 52.54 (NCH<sub>2</sub>CO), 60.99
(C-6<sub>gal</sub>), 67.16, 68.37, 70.35, 70.51, 72.53, 74.84 (C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>gal</sub>, C-4<sub>gal</sub>), 78.80 (C-1<sub>gal</sub>), 85.69 (C-4&#8242;<sub>ur</sub>), 95.84 (C-1&#8242;<sub>ur</sub>), 102.93 (C-5<sub>ur</sub>), 124.44 (C-5<sub>triaz</sub>), 144.41,
144.60 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.50 (C-2<sub>ur</sub>), 162.60 (C-4<sub>ur</sub>), 165.88, 169.18 (CONH), 169.61, 169.96,
170.31, 171.70 (CO). ESI-HRMS: calcd for C<sub>40</sub>H<sub>63</sub>N<sub>7</sub>O<sub>16</sub>Si<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 976.3768. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 976.3773.</p></sec><sec id="sec4.1.1.7"><label>4.1.1.7</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-deoxy-5&#8242;-[4-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-glucopyranosylthiomethyl)-1,2-3-triazol-1-yl]&#173;uridine (<bold>20</bold>)</title><p>The crude product was purified by column chromatography
(first toluene:ethyl acetate gradient from 4:1 to 1:1 and next CHCl<sub>3</sub>:MeOH, gradient from 100:1 to 80:1) to give <bold>20</bold> (143 mg, 80%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;20.0 (<italic toggle="yes">c</italic> = 0.5, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 103&#8211;107
&#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: 0.02,
0.07, 0.11 (3s, 12H, CH<sub>3</sub>Si), 0.87, 0.92 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 2.00, 2.02, 2.03, 2.08 (4s, 12H, CH<sub>3</sub>CO), 3.72 (ddd, 1H, <italic toggle="yes">J</italic> = 2.7 Hz, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-5<sub>glu</sub>), 3.90
and 4.09 (qAB, 2H, <italic toggle="yes">J</italic> = 14.3 Hz, CH<sub>2</sub>),
4.12&#8211;4.19 (m, 2H, H-6a<sub>glu</sub>, H-3&#8242;<sub>ur</sub>), 4.22 (dd, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> =
12.2 Hz, H-6b<sub>glu</sub>), 4.31 (m, 1H, H-4&#8242;<sub>ur</sub>), 4.42 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 5.5 Hz, H-2&#8242;<sub>ur</sub>), 4.59 (dd, 1H, <italic toggle="yes">J</italic> = 6.7 Hz, <italic toggle="yes">J</italic> = 14.2 Hz, H-5&#8242;a<sub>ur</sub>), 4.61 (d, 1H, <italic toggle="yes">J</italic> = 9.8 Hz, H-1<sub>glu</sub>), 4.67 (dd, 1H, <italic toggle="yes">J</italic> = 4.2 Hz, <italic toggle="yes">J</italic> =
14.2 Hz, H-5&#8242;b<sub>ur</sub>), 5.05 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-4<sub>glu</sub>), 5.10 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-2<sub>glu</sub>), 5.21 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.4 Hz, H-3<sub>glu</sub>), 5.47 (d, 1H, <italic toggle="yes">J</italic> = 5.5 Hz, H-1&#8242;<sub>ur</sub>), 5.73 (dd, 1H, <italic toggle="yes">J</italic> = 2.0 Hz, <italic toggle="yes">J</italic> =
8.2 Hz, H-5<sub>ur</sub>), 6.95 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz,
H-6<sub>ur</sub>), 7.61 (s, 1H, H-5<sub>triaz</sub>), 8.72 (s, 1H,
NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;4.71,
&#8722;4.68, &#8722;4.55, &#8722;4.31 (<underline>C</underline>H<sub>3</sub>Si), 17.94, 18.03 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.59, 20.61, 20.68, 20.79 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.74, 25.80 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 30.93 (CH<sub>2</sub>S), 51.35 (C-5&#8242;<sub>ur</sub>), 61.89, 68.26, 69.88, 72.73, 72.80, 73.79, 75.93 (C-6<sub>glu</sub>, C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>),
82.87, 82.93 (C-4&#8242;<sub>ur</sub>, C-1<sub>glu</sub>), 94.02
(C-1&#8242;<sub>ur</sub>), 102.67 (C-5<sub>ur</sub>), 123.95 (C-5<sub>triaz</sub>), 142.22, 144.70 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 149.84 (C-2<sub>ur</sub>), 162.62 (C-4<sub>ur</sub>), 169.42,
169.47, 170.16, 170.72 (CO). ESI-HRMS: calcd for C<sub>38</sub>H<sub>62</sub>N<sub>5</sub>O<sub>14</sub>SSi<sub>2</sub> [M + H]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 900.3553. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 900.3585.</p></sec><sec id="sec4.1.1.8"><label>4.1.1.8</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-deoxy-5&#8242;-[4-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-galactopyranosylthiomethyl)-1,2-3-triazol-1-yl]&#173;uridine (<bold>21</bold>)</title><p>The crude product was purified by column chromatography
(toluene:ethyl acetate gradient from 2:1 to 1:1) to give <bold>21</bold> (100 mg, 56%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;14.2 (<italic toggle="yes">c</italic> = 1, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 98&#8211;102
&#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: &#8722;0.01,
0.01, 0.07, 0.11 (4s, 12H, CH<sub>3</sub>Si), 0.87, 0.92 (2s, 18H,
(CH<sub>3</sub>)<sub>3</sub>C), 1.98, 2.04, 2.05, 2.15 (4s, 12H, CH<sub>3</sub>CO), 3.88&#8211;4.01 (m, 2H, CH, H-5<sub>gal</sub>), 4.04&#8211;4.20
(m, 4H, H-6a<sub>gal</sub>, H-6b<sub>gal</sub>, H-3&#8242;<sub>ur</sub>, CH), 4.31 (m, 1H, H-4&#8242;<sub>ur</sub>), 4.41 (dd &#8764;
t, 1H, <italic toggle="yes">J</italic> = 4.7 Hz, <italic toggle="yes">J</italic> = 5.1 Hz, H-2&#8242;<sub>ur</sub>), 4.53&#8211;4.71 (m, 3H, H-5&#8242;a<sub>ur</sub>, H-5&#8242;b<sub>ur</sub>, H-1<sub>gal</sub>), 5.04 (dd, 1H, <italic toggle="yes">J</italic> =
3.1 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-3<sub>gal</sub>), 5.25 (dd
&#8764; t, 1H, <italic toggle="yes">J</italic> = 9.8 Hz, <italic toggle="yes">J</italic> =
9.8 Hz, H-2<sub>gal</sub>), 5.43 (d, 1H, <italic toggle="yes">J</italic> = 3.1
Hz, H-4<sub>gal</sub>), 5.47 (d, 1H, <italic toggle="yes">J</italic> = 5.1 Hz,
H-1&#8242;<sub>ur</sub>), 5.74 (dd, 1H, <italic toggle="yes">J</italic> = 2.0
Hz, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 6.95 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 7.60 (s, 1H, H-5<sub>triaz</sub>), 8.50 (s, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)
&#948;: &#8722;4.73, &#8722;4.67, &#8722;4.54, &#8722;4.31 (<underline>C</underline>H<sub>3</sub>Si), 17.94, 18.03 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.58, 20.68, 20.72, 20.79 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.73, 25.79 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 24.29 (CH<sub>2</sub>S), 51.35 (C-5&#8242;<sub>ur</sub>), 61.32, 67.27, 71.77, 72.64, 72.77, 74.58 (C-6<sub>gal</sub>, C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>,
C-2&#8242;<sub>ur</sub>, C-3<sub>gal</sub>, C-4<sub>gal</sub>), 82.98,
83.40 (C-4&#8242;<sub>ur</sub>, C-1<sub>gal</sub>), 93.98 (C-1&#8242;<sub>ur</sub>), 102.68 (C-5<sub>ur</sub>), 125.29 (C-5<sub>triaz</sub>), 137.87, 142.25 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 149.77
(C-2<sub>ur</sub>), 162.452 (C-4<sub>ur</sub>), 169.69, 170.03, 170.22,
170.48 (CO). ESI-HRMS: calcd for C<sub>38</sub>H<sub>62</sub>N<sub>5</sub>O<sub>14</sub>SSi<sub>2</sub> [M + H]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 900.3553. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 900.3560.</p></sec><sec id="sec4.1.1.9"><label>4.1.1.9</label><title>
<italic toggle="yes">N</italic>-Uracil [(1-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-glucopyranosylthiomethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>22</bold>)</title><p>The crude product was purified by column
chromatography (toluene:ethyl acetate gradient from 2:1 to 1:1) to
give <bold>22</bold> (169 mg, 91%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;34.6 (<italic toggle="yes">c</italic> = 1, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 108&#8211;112 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: &#8722;0.11, 0.05, 0.12, 0.17 (4s, 12H,
CH<sub>3</sub>Si), 0.85, 0.93 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 2.00, 2.01, 2.02, 2.10 (4s, 12H, CH<sub>3</sub>CO), 3.71 (ddd,
1H, <italic toggle="yes">J</italic> = 2.7 Hz, <italic toggle="yes">J</italic> = 4.3 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-5<sub>glu</sub>), 4.09&#8211;4.19 (m, 2H,
H-6a<sub>glu</sub>, H-6b<sub>glu</sub>), 4.29 (dd, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 4.3 Hz, H-3&#8242;<sub>ur</sub>),
4.39 (d, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, H-4&#8242;<sub>ur</sub>), 4.52&#8211;4.68 (m, 4H,CH<sub>2</sub>, H-1<sub>glu</sub>, H-2&#8242;<sub>ur</sub>), 5.03 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-4<sub>glu</sub>), 5.09 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.0 Hz, <italic toggle="yes">J</italic> = 9.4 Hz, H-2<sub>glu</sub>), 5.20 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.4 Hz, H-3<sub>glu</sub>), 5.37 and 5.64 (qAB, 2H, <italic toggle="yes">J</italic> = 14.5 Hz, CH<sub>2</sub>), 5.48 (d, 1H, <italic toggle="yes">J</italic> = 7.0 Hz, H-1&#8242;<sub>ur</sub>), 5.78 (dd, 1H, <italic toggle="yes">J</italic> = 2.3 Hz, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 7.58 (d,
1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 7.76 (s, 1H, H-5<sub>triaz</sub>), 7.98 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 5.5 Hz, <italic toggle="yes">J</italic> = 5.9 Hz, NH), 8.73 (bs, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;5.02, &#8722;4.73, &#8722;4.67,
&#8722;4.53 (<underline>C</underline>H<sub>3</sub>Si), 17.89, 18.03
((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.55, 20.59,
20.81 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.70, 25.78 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 34.91 (<underline>C</underline>H<sub>
<underline>2</underline>
</sub>S), 48.50 (CH<sub>2</sub>NH),
61.64 (C-6<sub>glu</sub>), 67.96, 69.71, 71.33, 73.52, 74.79 (C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>), 82.26 <sub>(</sub>C-1<sub>glu</sub>), 85.12 (C-4&#8242;<sub>ur</sub>), 94.36 (C-1&#8242;<sub>ur</sub>), 102.80 (C-5<sub>ur</sub>), 121.97 (C-5<sub>triaz</sub>), 143.92, 145.30 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.38
(C-2<sub>ur</sub>), 162.55 (C-4<sub>ur</sub>), 169.35, 169.48, 170.00,
170.76 (CO). ESI-HRMS: calcd for C<sub>39</sub>H<sub>62</sub>N<sub>6</sub>O<sub>15</sub>SSi<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 965.3430. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 965.3432.</p></sec><sec id="sec4.1.1.10"><label>4.1.1.10</label><title>
<italic toggle="yes">N</italic>-Uracil [(1-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-Acetyl-&#946;-<sc>d</sc>-galactopyranosylthiomethyl)-1,2-3-triazol-4-yl)&#173;methyl]-1&#8242;-deoxy-2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-butyldimethylsilyl-&#946;-<sc>d</sc>-ribofuranuronamide
(<bold>23</bold>)</title><p>The crude product was purified by column
chromatography (toluene:ethyl acetate gradient from 2:1 to 1:1) to
give <bold>23</bold> (94 mg, 50%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;29.0 (<italic toggle="yes">c</italic> = 1, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 118&#8211;123 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) &#948;: &#8722;0.02, 0.05, 0.13, 0.18 (4s, 12H,
CH<sub>3</sub>Si), 0.85, 0.93 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 2.03, 2.06, 2.07, 2.17 (4s, 12H, CH<sub>3</sub>CO), 3.94 (ddd,
1H, <italic toggle="yes">J</italic> = 0.8 Hz, <italic toggle="yes">J</italic> = 5.5 Hz, <italic toggle="yes">J</italic> = 5.9 Hz, H-5<sub>gal</sub>), 4.01&#8211;4.09 (m, 2H,
H-6a<sub>gal</sub>, H-6b<sub>gal</sub>), 4.29 (dd, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, <italic toggle="yes">J</italic> = 4.3 Hz, H-3&#8242;<sub>ur</sub>),
4.39 (d, 1H, <italic toggle="yes">J</italic> = 1.6 Hz, H-4&#8242;<sub>ur</sub>), 4.52&#8211;4.69 (m, 4H,CH<sub>2</sub>, H-1<sub>gal</sub>, H-2&#8242;<sub>ur</sub>), 5.03 (dd, 1H, <italic toggle="yes">J</italic> = 3.5 Hz, <italic toggle="yes">J</italic> = 9.8 Hz, H-3<sub>gal</sub>), 5.23 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.8 Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-2<sub>gal</sub>), 5.39
and 5.65 (qAB, 2H, <italic toggle="yes">J</italic> = 14.5 Hz, CH<sub>2</sub>),
5.42 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 0.8 Hz, <italic toggle="yes">J</italic> = 3.5 Hz, H-4<sub>gal</sub>), 5.45 (d, 1H, <italic toggle="yes">J</italic> =
7.0 Hz, H-1&#8242;<sub>ur</sub>), 5.78 (dd, 1H, <italic toggle="yes">J</italic> = 2.0 Hz, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 7.54 (d,
1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 7.73 (s, 1H, H-5<sub>triaz</sub>), 8.03 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 5.5 Hz, <italic toggle="yes">J</italic> = 5.9 Hz, NH), 8.57 (bs, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) &#948;: &#8722;5.05, &#8722;4.72, &#8722;4.67,
&#8722;4.50 (<underline>C</underline>H<sub>3</sub>Si), 17.89, 18.03
((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.52, 20.64,
20.70, 20.73 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.70, 25.78
((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 34.92 (<underline>C</underline>H<sub>
<underline>2</underline>
</sub>S), 48.49 (CH<sub>2</sub>NH), 61.17 (C-6<sub>gal</sub>), 67.01, 67.07, 71.13, 71.51,
74.83, 74.91 (C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>gal</sub>, C-4<sub>gal</sub>), 82.76 (C-1<sub>gal</sub>), 85.20 (C-4&#8242;<sub>ur</sub>), 94.56
(C-1&#8242;<sub>ur</sub>), 102.84 (C-5<sub>ur</sub>), 121.88 (C-5<sub>triaz</sub>), 144.00, 145.33 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.37 (C-2<sub>ur</sub>), 162.33 (C-4<sub>ur</sub>), 169.50,
169.74, 169.82, 170.13 (CO). ESI-HRMS: calcd for C<sub>39</sub>H<sub>62</sub>N<sub>6</sub>O<sub>15</sub>SSi<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 965.3430. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 965.3433.</p></sec><sec id="sec4.1.1.11"><label>4.1.1.11</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-O-[(1-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-glucopyranosylthiomethyl)-1,2-3-triazol-4-yl)&#173;methyl]&#173;uridine
(<bold>24</bold>)</title><p>The crude product was purified by column
chromatography (toluene:ethyl acetate gradient from 4:1 to 2:1) to
give <bold>24</bold> (156 mg, 85%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;14.2 (<italic toggle="yes">c</italic> = 1, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 91&#8211;93 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) &#948;: 0.06, 0.07, 0.10 (3s, 12H, CH<sub>3</sub>Si), 0.89, 0.90 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C), 2.00, 2.01,
2.03, 2.09 (4s, 12H, CH<sub>3</sub>CO), 3.71 (dd, 1H, <italic toggle="yes">J</italic> = 2.0 Hz, <italic toggle="yes">J</italic> = 10.9 Hz, H-5&#8242;a<sub>ur</sub>), 3.75 (ddd, 1H, <italic toggle="yes">J</italic> = 2.3 Hz, <italic toggle="yes">J</italic> = 4.4 Hz, <italic toggle="yes">J</italic> = 10.0 Hz, H-5<sub>glu</sub>),3.91
(dd, 1H, <italic toggle="yes">J</italic> = 2.4 Hz, <italic toggle="yes">J</italic> = 10.9 Hz,
H-5&#8242;b<sub>ur</sub>), 4.07&#8211;4.16 (m, 4H, H-6a<sub>glu</sub>, H-2&#8242;<sub>ur</sub>, H-3&#8242;<sub>ur</sub>, H-4&#8242;<sub>ur</sub>), 4.21 (dd, 1H, <italic toggle="yes">J</italic> = 4.4 Hz, <italic toggle="yes">J</italic> = 12.6 Hz, H-6b<sub>glu</sub>), 4.65 (d, 1H, <italic toggle="yes">J</italic> =
10.0 Hz, H-1<sub>glu</sub>), 4.66 and 4.72 (qAB, 2H, <italic toggle="yes">J</italic> = 12.0 Hz, CH<sub>2</sub>), 5.08 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.0 Hz, H-4<sub>glu</sub>), 5.12
(dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 10.0 Hz, H-2<sub>glu</sub>), 5.21 (dd &#8764; t, 1H, <italic toggle="yes">J</italic> = 9.4 Hz, <italic toggle="yes">J</italic> = 9.4 Hz, H-3<sub>glu</sub>), 5.34 and 5.73 (qAB, 2H, <italic toggle="yes">J</italic> = 14.7 Hz, CH<sub>2</sub>), 5.64 (dd, 1H, <italic toggle="yes">J</italic> = 2.6 Hz, <italic toggle="yes">J</italic> =
8.2 Hz, H-5<sub>ur</sub>), 5.74 (d, 1H, <italic toggle="yes">J</italic> = 2.9 Hz,
H-1&#8242;<sub>ur</sub>), 7.72 (s, 1H, H-5<sub>triaz</sub>), 7.99
(d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz, H-6<sub>ur</sub>), 8.04 (bs,
1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) &#948;: &#8722;5.01,
&#8722;4.83, &#8211;4.58, &#8722;4.30 (<underline>C</underline>H<sub>3</sub>Si), 18.01, 18.09 ((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.56, 20.78 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.79, 25.83 ((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 48.27 (<underline>C</underline>H<sub>
<underline>2</underline>
</sub>N), 61.60, 64.36 (CH<sub>2</sub>O, C-6<sub>glu</sub>), 67.94,
68.43, 69.73, 70.63, 73.48, 75.83 (C-3&#8242;<sub>ur</sub>, C-2<sub>glu</sub>, C-5<sub>glu</sub>, C-2&#8242;<sub>ur</sub>, C-3<sub>glu</sub>, C-4<sub>glu</sub>), 81.97, 82.59 (C-1<sub>glu</sub>, C-4&#8242;<sub>ur</sub>), 89.76 (C-1&#8242;<sub>ur</sub>), 101.72 (C-5<sub>ur</sub>), 122.18 (C-5<sub>triaz</sub>), 140.74, 144.99 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.05 (C-2<sub>ur</sub>), 162.85 (C-4<sub>ur</sub>), 169.39, 170.00, 170.49 (CO). ESI-HRMS: calcd for C<sub>39</sub>H<sub>63</sub>N<sub>5</sub>O<sub>15</sub>SSi<sub>2</sub>Na
[M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 952.3478.
Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 952.3474.</p></sec><sec id="sec4.1.1.12"><label>4.1.1.12</label><title>2&#8242;,3&#8242;-di-O-<italic toggle="yes">tert</italic>-Butyldimethylsilyl-5&#8242;-O-[(1-(2&#8243;,3&#8243;,4&#8243;,6&#8243;-tetra-O-acetyl-&#946;-<sc>d</sc>-galactopyranosylthiomethyl)-1,2-3-triazol-4-yl)&#173;methyl]&#173;uridine
(<bold>25</bold>)</title><p>The crude product was purified by column
chromatography (toluene:ethyl acetate gradient from 4:1 to 2:1) to
give <bold>25</bold> (82 mg, 45%) as a white solid. [&#945;]<sub arrange="stack">
<italic toggle="yes">D</italic>
</sub>
<sup arrange="stack">20</sup> = &#8722;10.2 (<italic toggle="yes">c</italic> = 1, CHCl<sub>3</sub>), <italic toggle="yes">m.p.</italic> = 104&#8211;110 &#176;C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#948;: 0.06, 0.08, 0.11, 0.12 (4s, 12H, CH<sub>3</sub>Si), 0.89, 0.90 (2s, 18H, (CH<sub>3</sub>)<sub>3</sub>C),
1.98, 2.02, 2.05, 2.18 (4s, 12H, CH<sub>3</sub>CO), 3.72 (dd, 1H, <italic toggle="yes">J</italic> = 2.0 Hz, <italic toggle="yes">J</italic> = 10.6 Hz, H-5&#8242;a<sub>ur</sub>), 3.93&#8211;4.18 (m, 6H, H-5<sub>gal</sub>, H-6a<sub>gal</sub>, H-6b<sub>gal</sub>, H-2&#8242;<sub>ur</sub>, H-3&#8242;<sub>ur</sub>, H-4&#8242;<sub>ur</sub>), 4.65 (d, 1H, <italic toggle="yes">J</italic> = 9.8
Hz, H-1<sub>gal</sub>), 4.66 and 4.72 (qAB, 2H, <italic toggle="yes">J</italic> = 11.9 Hz, CH<sub>2</sub>), 5.06 (dd, 1H, <italic toggle="yes">J</italic> = 3.1
Hz, <italic toggle="yes">J</italic> = 10.2 Hz, H-3<sub>gal</sub>), 5.29 (dd &#8764;
t, 1H, <italic toggle="yes">J</italic> = 9.8 Hz, <italic toggle="yes">J</italic> = 10.2 Hz,
H-2<sub>gal</sub>), 5.35 and 5.77 (qAB, 2H, <italic toggle="yes">J</italic> = 14.6
Hz, CH<sub>2</sub>), 5.44 (dd, 1H, <italic toggle="yes">J</italic> = 0.9 Hz, <italic toggle="yes">J</italic> = 3.1 Hz, H-4<sub>gal</sub>), 5.62 (dd, 1H, <italic toggle="yes">J</italic> = 2.3 Hz, <italic toggle="yes">J</italic> = 8.2 Hz, H-5<sub>ur</sub>), 5.72 (d,
1H, <italic toggle="yes">J</italic> = 2.7 Hz, H-1&#8242;<sub>ur</sub>), 7.72 (s,
1H, H-5<sub>triaz</sub>), 8.01 (d, 1H, <italic toggle="yes">J</italic> = 8.2 Hz,
H-6<sub>ur</sub>), 8.31 (bs, 1H, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) &#948;: &#8722;4.92, &#8722;4.73, &#8722;4.43,
&#8722;4.17 (<underline>C</underline>H<sub>3</sub>Si), 148.14, 18.22
((CH<sub>3</sub>)<sub>3</sub>
<underline>C</underline>), 20.67, 20.77,
20.80, 20.81 (<underline>C</underline>H<sub>3</sub>)&#173;CO, 25.93, 25.96
((<underline>C</underline>H<sub>3</sub>)<sub>3</sub>C), 48.33 (<underline>C</underline>H<sub>
<underline>2</underline>
</sub>N), 61.10, 64.55
(CH<sub>2</sub>O, C-6<sub>gal</sub>), 67.09, 67.24, 68.53, 70.63,
71.59, 75.07, 75.95 (C-5&#8242;<sub>ur</sub>, C-3&#8242;<sub>ur</sub>, C-2<sub>gal</sub>, C-5<sub>gal</sub>, C-2&#8242;<sub>ur</sub>,
C-3<sub>gal</sub>, C-4<sub>gal</sub>), 82.52, 82.63 (C-4&#8242;<sub>ur</sub>, C-1<sub>gal</sub>), 90.02 (C-1&#8242;<sub>ur</sub>), 101.76
(C-5<sub>ur</sub>), 122.22 (C-5<sub>triaz</sub>), 140.89, 145.01 (C-6<sub>ur</sub>, C-4<sub>triaz</sub>), 150.23 (C-2<sub>ur</sub>), 163.18
(C-4<sub>ur</sub>), 169.76, 169.95, 170.23, 170.41 (CO). ESI-HRMS:
calcd for C<sub>39</sub>H<sub>63</sub>N<sub>5</sub>O<sub>15</sub>SSi<sub>2</sub>Na [M + Na]<sup>+</sup>: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 952.3478. Found: <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 952.3477.</p></sec></sec></sec><sec id="sec4.2"><label>4.2</label><title>Analyzed Compounds</title><p>The 10 mM stock
solutions of analyzed compounds and nirmatrelvir (Molport, SIA, Latvia)
were prepared in DMSO and stored at &#8722;20 &#176;C.</p></sec><sec id="sec4.3"><label>4.3</label><title>Cell Lines and Viruses</title><p>
<italic toggle="yes">Macaca
mulatta</italic> kidney epithelial cells (LLC-Mk2) were maintained
in minimal essential medium with one part of Earle&#8217;s MEM (Corning)
and two parts of Hank&#8217;s MEM (Corning) supplemented with 6%
fetal bovine serum (FBS, Thermo Scientific) and an Antibiotic Antimycotic
Solution (Thermo Scientific). Mouse L cells stably transfected with
mCEACAM-receptor (LR7) were maintained in Dulbecco&#8217;s modified
Eagle&#8217;s medium (Corning) supplemented with 5% FBS, Antibiotic
Antimycotic Solution, and 0.5 mg/mL G418 (Gibco). Human embryonic
kidney cells (HEK293T) and HEK293T cells stably producing ACE2 receptor<xref rid="ref44" ref-type="bibr"/> were maintained in Dulbecco&#8217;s modified
Eagle&#8217;s medium (Corning) supplemented with 8% FBS, 100 IU/ml
penicillin, and 100 &#956;g/mL streptomycin. SARS-CoV-2 replicon
containing BHK21 cell line was maintained in Dulbecco&#8217;s modified
Eagle&#8217;s medium supplemented with 8% FBS, 100 IU/ml penicillin,
100 &#956;g/mL streptomycin, and 200 &#956;g/mL G418.</p><p>Vero
cells (ATCC CCL-81) and Vero E6 cells (ATCC CRL-1586) were cultured
in Dulbecco&#8217;s modified Eagle&#8217;s medium (DMEM). The media
were supplemented with 10% (DMEM) newborn calf serum, 100 U/mL penicillin,
100 &#956;g/mL streptomycin, and 1% glutamine (Sigma-Aldrich, Prague,
Czech Republic). Vero and Vero E6 cells were cultured at 37 &#176;C
with 5% CO<sub>2</sub>.</p><p>HCoV-NL63 (isolate Amsterdam 1) and
MHV strain A59, a kind gift
of Prof. Krzysztof Pyr (Malopolska Centre of Biotechnology, Jagiellonian
University, Poland), were propagated in LLC-Mk2 and LR7, respectively.
Infected LLC-Mk2 cells were incubated for 9 days at 32 &#176;C under
5% CO<sub>2</sub>. LR7 cells infected with MHV were incubated at 37
&#176;C under 5% CO<sub>2</sub> for 2 days. Virus stocks were prepared
at the indicated time points by lysing the cells in two freeze&#8211;thaw
rounds. Medium containing the virus was aliquoted and stored in &#8722;70
&#176;C. Virus titer was determined by the plaque assay.</p><p>SARS-CoV-2
(strain SARS-CoV-2/human/Czech Republic/951/2020) was
isolated from a clinical specimen at the National Institute of Health,
Prague, Czech Republic, and was kindly provided by Dr. Jan Weber,
Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic.
Vero cells were used for SARS-CoV-2 propagation and for anti-SARS-CoV-2
assays, whereas Vero E6 cells were used for the plaque assay.</p></sec><sec id="sec4.4"><label>4.4</label><title>Cell Viability Assay</title><p>LR7, LLC-Mk2
or Vero cells were seeded in 96-well plates and cultured overnight.
Next, the medium was changed to a new one supplemented with different
concentrations (in triplicate) of analyzed compounds. Following the
2 days (LR7 and Vero) or 4 days (LLC-Mk-2) of incubation, CellTiter
96 AQ<sub>ueous</sub> nonradioactive cell proliferation assay (Promega)
was performed according to the manufacturer&#8217;s instruction.
The half-maximal cytotoxic concentration (CC<sub>50</sub>) was calculated
as the concentration of a compound needed to reduce cell viability
by 50% using GraphPad Prism software (version 5.01, GraphPad Software,
San Diego, CA).</p></sec><sec id="sec4.5"><label>4.5</label><title>Reduction of Virus Cytopathic
Effect</title><p>LR7 cells were seeded in a 96-well plate and cultured
overnight.
Next, the cells were infected with MHV at an MOI value of 0.01 in
medium without FBS. Following 1 h of incubation, the medium containing
the virus was collected and cells were covered with a medium supplemented
with different concentrations (in triplicate) of the analyzed compounds
or DMSO. 24 h p.i. cells viability was evaluated by CellTiter 96 AQ<sub>ueous</sub> nonradioactive cell proliferation assay (Promega) according
to the manufacturer&#8217;s instruction.</p></sec><sec id="sec4.6"><label>4.6</label><title>Dose-Dependent
Anticoronavirus Activity of
Compounds</title><p>LR7 or LLC-Mk2 cells were infected at a MOI of
0.01 with MHV and HCoV-NL63, respectively, and treated with selected
compounds at a concentration ranging from 0 to 50 &#956;M. Culture
supernatants were collected 1 day (MHV) or 4 days (HCoV-NL63) after
infection. Virus titer was determined by plaque assay.</p><p>Vero
cells were seeded in appropriate plates and allowed to reach an approximately
90% confluence. For infection, 200 &#956;L of viral suspension containing
10<sup>5</sup> pfu (SARS-CoV-2 strain SARS-CoV-2/human/Czech Republic/951/2020)
was added to each well and incubated for 2 h at 37&#8239;&#176;C
to allow virus adsorption. After the incubation, the viral medium
was removed, and the wells were washed gently with phosphate-buffered
saline (PBS). Test compounds were prepared in serial dilutions to
final concentrations of 50, 25, 12.5, 6.25, 3.125, and 0 &#956;M
in the medium (DMEM containing 2% FBS). The compounds were added in
quadruplicate to the infected cells. The plates were then incubated
for 48 h at 37&#8239;&#176;C. Following the 48 h treatment period,
the supernatants were removed, and plaque assays in Vero E6 cells
were performed to assess viral titers. Cells were fixed and stained
4 days after infection to visualize plaques, as described previously.<xref rid="ref45" ref-type="bibr"/>
</p><p>The half-maximum inhibitory concentration
value (IC<sub>50</sub>) indicating the concentration of compound needed
to reduce virus
titer by 50% in comparison to the control, was evaluated by GraphPad
software (version 5.01, GraphPad Software, San Diego, CA).</p></sec><sec id="sec4.7"><label>4.7</label><title>Western Blot Analysis</title><p>LLC-Mk2 monolayers
grown in 24-well plates were infected with HCoV-NL63 at an MOI value
of 0.01 for 2 h. Unbound virus was removed, and cells were cultured
in medium supplemented with different concentrations of compounds.
Four days postinfection, cells were collected and lysed in CellLyticM
Cell Lysis Reagent (Sigma). Following the protein separation by SDS-PAGE
and transfer to PVDF membranes, proteins were immunoblotted using
specific mouse anti-N NL63 Abs (Eurofins, Spain) or rabbit anti-&#946;-catenin
Abs (Santa Cruz), followed by antimouse or antirabbit secondary antibodies
conjugated with HRP. Proteins were visualized and analyzed by chemiluminescence
using the UVITEC Cambridge Alliance MINI HD detection system. The
densitometric analysis of cells treated with 50 &#956;M dose of a
panel of glycoconjugates was performed based on three biological replicates
of N and &#946;-catenin immunoblots. The N protein levels were expressed
as a percentage relative to DMSO-treated infected cells, while &#946;-catenin
levels were expressed as a percentage relative to noninfected control
cells. The data were presented as the ratio of N/&#946;-catenin for
each sample, normalized accordingly.</p></sec><sec id="sec4.8"><label>4.8</label><title>SARS-CoV-2
VLP Internalization Assay</title><p>SARS-CoV-2 VLP internalization
assay was performed according to the
protocol published by Syed et al. with some modifications.<xref rid="ref32" ref-type="bibr"/> Seven &#215; 10<sup>5</sup> HEK293T cells were
seeded into each well of the six-well plate. Next day, cells on each
well were transfected with 1 &#956;g of LucPS9 (addgene no. 177942),
1.35 &#956;g of CoV-2-N-WT-Hu1 (addgene no. 177937), 0.6 &#956;g
of CoV2-M-IRES-E (addgene no. 177938), and 50 ng of CoV2-Spike-EF1a-D614G-N501Y
(addgen no. 177939) using jetPRIME transfection reagent according
to the manufacturer&#8217;s protocol. Briefly, DNA was mixed with
200 &#956;L of jetPRIME buffer, and subsequently, 6 &#956;L of jetPRIME
reagent was added to the mixture, vortexed, and incubated for 10 min.
Next transfection mixture was added by droplets onto cells. 4 h post-transfection
(p.t.) medium was changed to one supplemented with different concentrations
of the analyzed compounds. 48 h p.t. SC-VLP-containing medium was
collected and filtered by a 0.45 &#956;m PVDF filter. Remaining cells
were collected and lysed in CellLytic buffer (Sigma) or 1% digitonin.</p><p>50 &#956;L of SC-VLP containing medium was added to 3 &#215; 10<sup>4</sup> HEK293T or HEK293T hACE2 cells freshly seeded on a 96-well
plate in 50 &#956;L of medium and incubated. After 24 h, the cells
were lysed using 100 &#956;L per well of Glo Lysis Buffer (Promega).
Luciferase expression was analyzed by Bright-Glo Luciferase Assay
(Promega) according to the manufacturer&#8217;s protocol.</p><p>SC-VLPs
were precipitated using 10% PEG6000 with 0.3 M NaCl and
resuspended in 30 &#956;L of PBS buffer. Following the protein separation
by SDS-PAGE and transfer to PVDF membranes, proteins were immunoblotted
using specific rabbit anti-S2 Abs (Sino Biological Europe GmbH, Germany)
or rabbit anti-&#946;-catenin Abs (Santa Cruz) followed by antirabbit
secondary antibodies conjugated with HRP. Proteins were visualized
by chemiluminescence using the UVITEC Cambridge Alliance MINI HD detection
system.</p></sec><sec id="sec4.9"><label>4.9</label><title>Viral RNA Isolation and PCR Assay</title><p>LR7 or LLC-Mk2 were cultured in 12-well plate overnight. Next, LR7
cells were infected with MHV at an MOI value of 1 for 1 h or LLC-Mk2
cells were infected with HCoV-NL63 at an MOI value of 0.01 for 2 h.
Following removal of unbound virus, cells were cultured with medium
supplemented with different concentrations of selected compounds.
8 h p.i. (MHV) or 96 h p.i. (HCoV-NL63) cells were collected and total
RNA was isolated by CoV RNA kit (A&amp;A Biotechnology, Poland) according
to the manufacturer&#8217;s instruction. To evaluate levels of viral
RNA in infected cells Qiagen One-Step RT-PCR reaction was performed.
Following reverse transcription, the PCR reaction was carried out
using primers: F: GATGGTGTTGTTTGGGTTGC, R: CTGTGGAAAACCTTTGGCATC for
amplification of a fragment of HCoV-NL63 genome (position: 26418&#8211;26960
bp <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NC_005831.2">NC_005831.2</ext-link>) and F: TGGCCGAAGAAATTGCTGCTCTTG and R: TGCACAGAGCTTTTGGGCTTTGC
for amplification of a fragment of MHV genome (position: 30341&#8211;30902
bp <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="FJ647225.1">FJ647225.1</ext-link>). For internal control fragment of &#946;-actin mRNA
was reverse transcribed and amplified using primers For: GCGGGAAATCGTGCGTGACATT
and Rev: GATGGAGTTGAAGGTAGTTTCGTG.</p></sec><sec id="sec4.10"><label>4.10</label><title>Inhibition
of SARS-CoV-2 Replication</title><p>The protocol for SARS-CoV-2 replicon
containing BHK21 cell line treatment
was conducted according to Liu et al.<xref rid="ref34" ref-type="bibr"/> In brief: Compounds were diluted in DMEM cell culture medium with
8% FBS to a final concentration of 25 &#956;M. The SARS-CoV-2-Rep-NanoLuc-Neo
BHK21 cells were seeded at 1.5 &#215; 10<sup>4</sup> per well in a
96-well plate in triplicate and incubated at 37 &#176;C, 5% CO<sub>2</sub>. 24 h after seeding, the cell culture medium was replaced
with the media containing compounds and incubated at 37 &#176;C, 5%
CO<sub>2</sub> for 48 h. After that time, the cells were assayed for
NanoLuc activity with Nano-Glo Luciferase Assay System (Promega),
and luminescence signal was assessed in a microplate reader (Infinite
200, Tecan). All compounds were tested in at least three biological
replicates.</p></sec><sec id="sec4.11"><label>4.11</label><title>Statistical Analysis</title><p>All statistical
analyses were performed using GraphPad Prism 5 software. Statistical
significance was determined using a <italic toggle="yes">t</italic> test or Dunnett&#8217;s
One-way ANOVA test.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01602_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01602_si_002.csv" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e3834-autogenerated"><p>The authors
thank Krzysztof Pyr&#263; from the Malopolska
Centre of Biotechnology, Jagiellonian University, Poland for the MHV
strain A59 and HCoV-NL63 viruses. The following reagent was obtained
through BEI Resources, NIAID, NIH: Human Embryonic Kidney Cells (HEK293T)
expressing Human Angiotensin-Converting Enzyme 2, HEK293T-hACE2 Cell
Line, and NR-52511 and BHK-21 Cell Line Harboring SARS-CoV-2-Replicon
Containing NanoLuc -Neo Reporters and NSP1Mutations (K164A/H165A),
NR-58876.</p></ack><notes id="notes-1" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01602?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01602</ext-link>.<list list-type="simple" id="silist"><list-item><p>1H NMR spectra and HRMS
of analyzed compounds. Immunodetection
of S and N proteins in SC-VLP-producing cells (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01602/suppl_file/jm5c01602_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>A file containing the compound
numbers described in
the publication, along with their corresponding Molecular Formula
Strings, has been included in the submitted materials (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01602/suppl_file/jm5c01602_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-3" notes-type="funding-statement"><p>This
work was
funded by the National Science Centre, Poland, grant numbers UMO-2020/01/0/NZ6/00146
and UMO-2021/41/B/NZ6/02628. P.S. and D.R. were supported by the National
Institute of Virology and Bacteriology (Programme EXCELES, ID Project
No. LX22NPO5103), funded by the European Union&#58872;Next Generation
EU.</p></notes><notes id="notes-2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations Used</title><def-item><term>&#946;4GalT</term><def><p>&#946;-1,4-galactosyltransferase</p></def></def-item><def-item><term>ACE2</term><def><p>angiotensin-converting
enzyme 2</p></def></def-item><def-item><term>BHK21</term><def><p>baby
hamster kidney 21 (cells)</p></def></def-item><def-item><term>CPE</term><def><p>cytopathic effect</p></def></def-item><def-item><term>CuAAC</term><def><p>copper&#173;(i)-catalyzed 1,3-dipolar azido-alkyne cycloaddition</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#8217;s
modified Eagle&#8217;s medium</p></def></def-item><def-item><term>DMV</term><def><p>double membrane vesicle</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>GT</term><def><p>glycosyltransferase</p></def></def-item><def-item><term>hCoV</term><def><p>human coronavirus</p></def></def-item><def-item><term>HRP</term><def><p>horseradish peroxidase</p></def></def-item><def-item><term>LLC-Mk2</term><def><p>
<italic toggle="yes">Macaca
mulatta</italic> kidney epithelial cells</p></def></def-item><def-item><term>mCEACAM</term><def><p>murine carcinoembryonic antigen-related
cell adhesion molecule</p></def></def-item><def-item><term>MEM</term><def><p>minimal essential medium</p></def></def-item><def-item><term>MERS-CoV</term><def><p>middle east respiratory syndrome coronavirus</p></def></def-item><def-item><term>MHV</term><def><p>murine hepatitis
virus</p></def></def-item><def-item><term>MOI</term><def><p>multiplicity
of infection</p></def></def-item><def-item><term>MTS</term><def><p>3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium</p></def></def-item><def-item><term>NaAsc</term><def><p>sodium ascorbate</p></def></def-item><def-item><term>N</term><def><p>nucleocapsid (protein)</p></def></def-item><def-item><term>PFU</term><def><p>plaque-forming
unit</p></def></def-item><def-item><term>PMS</term><def><p>phenazine
methosulfate</p></def></def-item><def-item><term>S</term><def><p>spike
(protein)</p></def></def-item><def-item><term>SARS-CoV</term><def><p>severe acute respiratory syndrome coronavirus</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>severe acute respiratory
syndrome coronavirus 2</p></def></def-item><def-item><term>SI</term><def><p>selectivity index</p></def></def-item><def-item><term>TBDMS</term><def><p>
<italic toggle="yes">tert</italic>-butyldimethylsilyl</p></def></def-item><def-item><term>VLP</term><def><p>virus-like particle</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>van
der Hoek</surname><given-names>L.</given-names></name><article-title>Human Coronaviruses: What Do They Cause?</article-title><source>Antivir. Ther.</source><year>2007</year><volume>12</volume><issue>4 Pt B</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1177/135965350701200S01.1</pub-id><pub-id pub-id-type="pmid">17944272</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Woo</surname><given-names>P. C. Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S. K. P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name><article-title>Coronavirus
Diversity,
Phylogeny and Interspecies Jumping</article-title><source>Exp. Biol.
Med. Maywood NJ.</source><year>2009</year><volume>234</volume><issue>10</issue><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.3181/0903-MR-94</pub-id><pub-id pub-id-type="pmid">19546349</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>V&#8217;kovski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kratzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>V.</given-names></name><article-title>Coronavirus
Biology and Replication: Implications for SARS-CoV-2</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><issue>3</issue><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id><pub-id pub-id-type="pmcid">PMC7592455</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>K&#246;rner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Majjouti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alcazar</surname><given-names>M. A. A.</given-names></name><name name-style="western"><surname>Mahabir</surname><given-names>E.</given-names></name><article-title>Of Mice and Men: The
Coronavirus MHV and Mouse Models as a Translational Approach to Understand
SARS-CoV-2</article-title><source>Viruses</source><year>2020</year><volume>12</volume><issue>8</issue><elocation-id>880</elocation-id><pub-id pub-id-type="doi">10.3390/v12080880</pub-id><pub-id pub-id-type="pmid">32806708</pub-id><pub-id pub-id-type="pmcid">PMC7471983</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Agostini</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Andres</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Case</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Cihlar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mackman</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name><article-title>Coronavirus Susceptibility
to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase
and the Proofreading Exoribonuclease</article-title><source>mBio</source><year>2018</year><volume>9</volume><issue>2</issue><elocation-id>e00221&#8211;18</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id><pub-id pub-id-type="pmid">29511076</pub-id><pub-id pub-id-type="pmcid">PMC5844999</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>van
der Hoek</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pyrc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berkhout</surname><given-names>B.</given-names></name><article-title>Human Coronavirus NL63,
a New Respiratory Virus</article-title><source>FEMS Microbiol. Rev.</source><year>2006</year><volume>30</volume><issue>5</issue><fpage>760</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2006.00032.x</pub-id><pub-id pub-id-type="pmid">16911043</pub-id><pub-id pub-id-type="pmcid">PMC7109777</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Milewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciejka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bielska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zeglen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karolak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nowakowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Potempa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Pyrc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szczubialka</surname><given-names>K.</given-names></name><article-title>Novel Polymeric
Inhibitors of HCoV-NL63</article-title><source>Antiviral Res.</source><year>2013</year><volume>97</volume><issue>2</issue><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.11.006</pub-id><pub-id pub-id-type="pmid">23201315</pub-id><pub-id pub-id-type="pmcid">PMC7114096</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Milewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Szczepanski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barreto-Duran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dabrowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Botwina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Obloza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ochman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urlik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodziewicz-Motowidlo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Szczubialka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nowakowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pyrc</surname><given-names>K.</given-names></name><article-title>HTCC as a Polymeric
Inhibitor of SARS-CoV-2 and MERS-CoV</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><issue>4</issue><elocation-id>e01622&#8211;20</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01622-20</pub-id><pub-id pub-id-type="pmid">33219167</pub-id><pub-id pub-id-type="pmcid">PMC7851557</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Barghash</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Gemmati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Elbakry</surname><given-names>M. M. M.</given-names></name><name name-style="western"><surname>Tisato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Awad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A. V.</given-names></name><article-title>Navigating
the COVID-19 Therapeutic
Landscape: Unveiling Novel Perspectives on FDA-Approved Medications,
Vaccination Targets, and Emerging Novel Strategies</article-title><source>Mol. Basel Switz.</source><year>2024</year><volume>29</volume><issue>23</issue><elocation-id>5564</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29235564</pub-id><pub-id pub-id-type="pmcid">PMC11643501</pub-id><pub-id pub-id-type="pmid">39683724</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Luytjes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sturman</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Bredenbeek</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Charite</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der
Zeijst</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Horzinek</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Spaan</surname><given-names>W. J.</given-names></name><article-title>Primary Structure
of the Glycoprotein E2 of Coronavirus MHV-A59 and Identification of
the Trypsin Cleavage Site</article-title><source>Virology</source><year>1987</year><volume>161</volume><issue>2</issue><fpage>479</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(87)90142-5</pub-id><pub-id pub-id-type="pmid">2825419</pub-id><pub-id pub-id-type="pmcid">PMC7130946</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Frenz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>DiMaio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name><article-title>Glycan Shield
and Epitope Masking of a Coronavirus Spike Protein Observed by Cryo-Electron
Microscopy</article-title><source>Nat. Struct. Mol. Biol.</source><year>2016</year><volume>23</volume><issue>10</issue><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3293</pub-id><pub-id pub-id-type="pmid">27617430</pub-id><pub-id pub-id-type="pmcid">PMC5515730</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Fung</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D. X.</given-names></name><article-title>Post-Translational
Modifications of Coronavirus Proteins:
Roles and Function</article-title><source>Future Virol.</source><year>2018</year><volume>13</volume><issue>6</issue><fpage>405</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.2217/fvl-2018-0008</pub-id><pub-id pub-id-type="pmid">32201497</pub-id><pub-id pub-id-type="pmcid">PMC7080180</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name><article-title>Structure, Function,
and Antigenicity of the SARS-CoV-2
Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>183</volume><issue>6</issue><elocation-id>1735</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.032</pub-id><pub-id pub-id-type="pmid">33306958</pub-id><pub-id pub-id-type="pmcid">PMC7833104</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Crispin</surname><given-names>M.</given-names></name><article-title>Site-Specific
Glycan Analysis of the SARS-CoV-2 Spike</article-title><source>Science</source><year>2020</year><volume>369</volume><issue>6501</issue><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmid">32366695</pub-id><pub-id pub-id-type="pmcid">PMC7199903</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Ram&#237;rez
Hern&#225;ndez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Zimbr&#243;n</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Mart&#237;nez Z&#250;&#241;iga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leal-Garc&#237;a</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Ignacio Hern&#225;ndez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ucharima-Corona</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>P&#233;rez Campos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zenteno</surname><given-names>E.</given-names></name><article-title>The Role of the SARS-CoV-2 S-Protein
Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological
Responses</article-title><source>Viral Immunol.</source><year>2021</year><volume>34</volume><issue>3</issue><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1089/vim.2020.0174</pub-id><pub-id pub-id-type="pmid">33605822</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Breton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fournel-Gigleux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palcic</surname><given-names>M. M.</given-names></name><article-title>Recent Structures, Evolution and
Mechanisms of Glycosyltransferases</article-title><source>Curr. Opin.
Struct. Biol.</source><year>2012</year><volume>22</volume><issue>5</issue><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2012.06.007</pub-id><pub-id pub-id-type="pmid">22819665</pub-id></element-citation></ref><ref id="ref17"><mixed-citation publication-type="book" id="cit17"><source>Handbook of Glycosyltransferases and Related Genes</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Taniguchi</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western"><surname>Honke</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Fukuda</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Narimatsu</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Yamaguchi</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Angata</surname>, <given-names>T.</given-names></string-name></person-group>, Eds.; <publisher-name>Springer Japan</publisher-name>: <publisher-loc>Tokyo</publisher-loc>, <year>2014</year><pub-id pub-id-type="doi">10.1007/978-4-431-54240-7</pub-id>.</mixed-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chaubey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krol</surname><given-names>E.</given-names></name><article-title>Novel Thioglycosyl
Analogs of Glycosyltransferase Substrates as Antiviral Compounds against
Classical Swine Fever Virus and Hepatitis C Virus</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>137</volume><fpage>247</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.05.051</pub-id><pub-id pub-id-type="pmid">28601004</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Brzuska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krol</surname><given-names>E.</given-names></name><article-title>Anti-Tick-Borne
Encephalitis Virus Activity of Novel Uridine Glycoconjugates Containing
Amide or/and 1,2,3-Triazole Moiety in the Linker Structure</article-title><source>Pharm. Basel Switz.</source><year>2020</year><volume>13</volume><issue>12</issue><elocation-id>E460</elocation-id><pub-id pub-id-type="doi">10.3390/ph13120460</pub-id><pub-id pub-id-type="pmcid">PMC7764612</pub-id><pub-id pub-id-type="pmid">33322151</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Krol</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chaubey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brzuska</surname><given-names>G.</given-names></name><name name-style="western"><surname>Erfurt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name><article-title>Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl
1-Thioglycosides, as Potential Antiviral Compounds</article-title><source>Molecules</source><year>2018</year><volume>23</volume><issue>6</issue><elocation-id>1435</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23061435</pub-id><pub-id pub-id-type="pmid">29899276</pub-id><pub-id pub-id-type="pmcid">PMC6100568</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Ghosh</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Brindisi</surname><given-names>M.</given-names></name><article-title>Organic Carbamates in Drug Design
and Medicinal Chemistry</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><issue>7</issue><fpage>2895</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1021/jm501371s</pub-id><pub-id pub-id-type="pmid">25565044</pub-id><pub-id pub-id-type="pmcid">PMC4393377</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Kolb</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Sharpless</surname><given-names>K. B.</given-names></name><article-title>Click Chemistry:
Diverse Chemical
Function from a Few Good Reactions</article-title><source>Angew. Chem.,
Int. Ed.</source><year>2001</year><volume>40</volume><issue>11</issue><fpage>2004</fpage><lpage>2021</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-3773(20010601)40:11&amp;#x0003c;2004::AID-ANIE2004&amp;#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">11433435</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Behr</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Gourlain</surname><given-names>T.</given-names></name><name name-style="western"><surname>Helimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guillerm</surname><given-names>G.</given-names></name><article-title>Design, Synthesis and
Biological Evaluation of Hetaryl-Nucleoside Derivatives as Inhibitors
of Chitin Synthase</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2003</year><volume>13</volume><issue>10</issue><fpage>1713</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(03)00239-7</pub-id><pub-id pub-id-type="pmid">12729648</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Krawczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mrozek-Wilczkiewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skonieczna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musiol</surname><given-names>R.</given-names></name><article-title>Synthesis of 8-Hydroxyquinoline Glycoconjugates and
Preliminary Assay of Their B1,4-GalT Inhibitory and Anti-Cancer Properties</article-title><source>Bioorganic Chem.</source><year>2019</year><volume>84</volume><fpage>326</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.11.047</pub-id><pub-id pub-id-type="pmid">30530074</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Le
Roux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meunier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Le Gall</surname><given-names>T.</given-names></name><name name-style="western"><surname>Denis</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>A.</given-names></name><article-title>Synthesis and Radioprotective Properties of Pulvinic
Acid Derivatives</article-title><source>ChemMedChem.</source><year>2011</year><volume>6</volume><issue>3</issue><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201000391</pub-id><pub-id pub-id-type="pmid">21246736</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Mereyala</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Gurrala</surname><given-names>S. R.</given-names></name><article-title>A Highly Diastereoselective,
Practical Synthesis of
Allyl, Propargyl 2,3,4,6-Tetra-O-Acetyl-&#946;-d-Gluco, &#946;-d-Galactopyranosides
and Allyl, Propargyl Heptaacetyl-&#946;-d-Lactosides</article-title><source>Carbohydr. Res.</source><year>1998</year><volume>307</volume><issue>3</issue><fpage>351</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0008-6215(97)10104-5</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>More</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Chiao</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Jao</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.-S.</given-names></name><article-title>Glycosylation Enhances
the Anti-Migratory Activities of Isomalyngamide
A Analogs</article-title><source>Eur. J. Med. Chem.</source><year>2013</year><volume>64</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.03.044</pub-id><pub-id pub-id-type="pmid">23644200</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Pietrzik</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schips</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>T.</given-names></name><article-title>Efficient
Synthesis of Glycosylated
Asparaginic Acid Building Blocks via Click Chemistry</article-title><source>Synthesis</source><year>2008</year><volume>2008</volume><issue>4</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1032150</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>R. R.</given-names></name><article-title>Glycosylthiomethyl Chloride: A New Species for S-Neoglycoconjugate
Synthesis. Synthesis of 1-<italic toggle="yes">N</italic>-Glycosylthiomethyl-1,2,3-Triazoles</article-title><source>J. Org. Chem.</source><year>2004</year><volume>69</volume><issue>4</issue><fpage>1081</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1021/jo035300o</pub-id><pub-id pub-id-type="pmid">14961655</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Witczak</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Sarnik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Czubatka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Forma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Poplawski</surname><given-names>T.</given-names></name><article-title>Thio-Sugar
Motif of Functional CARB-Pharmacophore for Antineoplastic Activity.
Part 2</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2014</year><volume>24</volume><issue>24</issue><fpage>5606</fpage><lpage>5611</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2014.10.095</pub-id><pub-id pub-id-type="pmid">25466184</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Pastuch-Gawo&#322;ek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mrozek-Wilczkiewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Musio&#322;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Czaplinska</surname><given-names>B.</given-names></name><name name-style="western"><surname>Musiol</surname><given-names>R.</given-names></name><article-title>Small Molecule Glycoconjugates
with Anticancer Activity</article-title><source>Eur. J. Med. Chem.</source><year>2016</year><volume>112</volume><fpage>130</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.01.061</pub-id><pub-id pub-id-type="pmid">26890119</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Syed</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Tabata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>I. P.</given-names></name><name name-style="western"><surname>Ciling</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Sreekumar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Soczek</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doudna</surname><given-names>J. A.</given-names></name><article-title>Rapid Assessment
of SARS-CoV-2&#8211;Evolved Variants Using Virus-like Particles</article-title><source>Science</source><year>2021</year><volume>374</volume><issue>6575</issue><fpage>1626</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.1126/science.abl6184</pub-id><pub-id pub-id-type="pmid">34735219</pub-id><pub-id pub-id-type="pmcid">PMC9005165</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Krol</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wandzik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pastuch-Gawolek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>B.</given-names></name><article-title>Anti-Hepatitis C Virus
Activity of Uridine Derivatives of 2-Deoxy Sugars</article-title><source>Molecules</source><year>2018</year><volume>23</volume><issue>7</issue><elocation-id>1547</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23071547</pub-id><pub-id pub-id-type="pmid">29954068</pub-id><pub-id pub-id-type="pmcid">PMC6099588</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. T.</given-names></name><article-title>Stable
Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><issue>6</issue><elocation-id>e0221621</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.02216-21</pub-id><pub-id pub-id-type="pmid">35080424</pub-id><pub-id pub-id-type="pmcid">PMC8941906</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Holmes</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Doller</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Sturman</surname><given-names>L. S.</given-names></name><article-title>Tunicamycin
Resistant Glycosylation
of a Coronavirus Glycoprotein: Demonstration of a Novel Type of Viral
Glycoprotein</article-title><source>Virology</source><year>1981</year><volume>115</volume><issue>2</issue><fpage>334</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(81)90115-X</pub-id><pub-id pub-id-type="pmid">7314449</pub-id><pub-id pub-id-type="pmcid">PMC7130623</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Casas-Sanchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romero-Ramirez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Grajeda</surname><given-names>B. I.</given-names></name><name name-style="western"><surname>Estevao</surname><given-names>I. L.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Zech</surname><given-names>T.</given-names></name><name name-style="western"><surname>Acosta-Serrano</surname><given-names>&#193;.</given-names></name><article-title>Inhibition of Protein <italic toggle="yes">N</italic>-Glycosylation Blocks SARS-CoV-2 Infection</article-title><source>mBio</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>e0371821</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03718-21</pub-id><pub-id pub-id-type="pmcid">PMC8844921</pub-id><pub-id pub-id-type="pmid">35164559</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Gadlage</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Beachboard</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Stobart</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M. R.</given-names></name><article-title>Murine Hepatitis Virus Nonstructural
Protein 4 Regulates Virus-Induced Membrane Modifications and Replication
Complex Function</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><issue>1</issue><fpage>280</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1128/JVI.01772-09</pub-id><pub-id pub-id-type="pmid">19846526</pub-id><pub-id pub-id-type="pmcid">PMC2798404</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>S&#248;rensen</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>B&#252;ll</surname><given-names>C.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Lira-Navarrete</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Garretson</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pijnenborg</surname><given-names>J. F. A.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Chanda</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Boltje</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Schjoldager</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Vakhrushev</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Halim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esko</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Hurtado-Guerrero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weigert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Narimatsu</surname><given-names>Y.</given-names></name><article-title>Identification
of Global Inhibitors of Cellular Glycosylation</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><issue>1</issue><elocation-id>948</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-36598-7</pub-id><pub-id pub-id-type="pmid">36804936</pub-id><pub-id pub-id-type="pmcid">PMC9941569</pub-id></element-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Ferjancic</surname>, <given-names>Z.</given-names></string-name>; <string-name name-style="western"><surname>Bihelovic</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Vulovic</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western"><surname>Matovic</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Trmcic</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Jankovic</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Pavlovic</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Djurkovic</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Prodanovic</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Djurdjevic Djelmas</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Kalicanin</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western"><surname>Zlatovic</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Sladic</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western"><surname>Vallet</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Vignuzzi</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Saicic</surname>, <given-names>R. N.</given-names></string-name></person-group><article-title>Development of Iminosugar-Based Glycosidase Inhibitors as Drug Candidates
for SARS-CoV-2 Virus via Molecular Modelling and in Vitro Studies</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source><year>2024</year><volume>39</volume> (<issue>1</issue>), <elocation-id>2289007</elocation-id>. <pub-id pub-id-type="doi">10.1080/14756366.2023.2289007</pub-id>.<pub-id pub-id-type="pmid">38086763</pub-id><pub-id pub-id-type="pmcid">PMC11721942</pub-id></mixed-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Rajasekharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milan Bonotto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nascimento Alves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kazungu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Poggianella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Orellana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skoko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Polez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marcello</surname><given-names>A.</given-names></name><article-title>Inhibitors
of Protein Glycosylation Are Active against the Coronavirus Severe
Acute Respiratory Syndrome Coronavirus SARS-CoV-2</article-title><source>Viruses</source><year>2021</year><volume>13</volume><issue>5</issue><elocation-id>808</elocation-id><pub-id pub-id-type="doi">10.3390/v13050808</pub-id><pub-id pub-id-type="pmid">33946304</pub-id><pub-id pub-id-type="pmcid">PMC8144969</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Block</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Tennant</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ebling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korba</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lansky</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Dwek</surname><given-names>R. A.</given-names></name><article-title>Treatment
of Chronic Hepadnavirus Infection in a Woodchuck Animal Model with
an Inhibitor of Protein Folding and Trafficking</article-title><source>Nat. Med.</source><year>1998</year><volume>4</volume><issue>5</issue><fpage>610</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1038/nm0598-610</pub-id><pub-id pub-id-type="pmid">9585237</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Tierney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pottage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Merigan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Powderly</surname><given-names>W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>J.</given-names></name><article-title>The Tolerability and Pharmacokinetics of N-Butyl-Deoxynojirimycin
in Patients with Advanced HIV Disease (ACTG 100)</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>1995</year><volume>10</volume><issue>5</issue><elocation-id>549</elocation-id><pub-id pub-id-type="doi">10.1097/00042560-199510050-00008</pub-id><pub-id pub-id-type="pmid">8548334</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Durantel</surname><given-names>D.</given-names></name><article-title>Celgosivir,
an Alpha-Glucosidase I Inhibitor for the Potential Treatment of HCV
Infection</article-title><source>Curr. Opin. Investig. Drugs London
Engl. 2000</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>860</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">19649930</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Crawford</surname><given-names>K. H. D.</given-names></name><name name-style="western"><surname>Eguia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dingens</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Loes</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pettie</surname><given-names>D.</given-names></name><name name-style="western"><surname>King</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Balazs</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>J. D.</given-names></name><article-title>Protocol and Reagents for Pseudotyping
Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization
Assays</article-title><source>Viruses</source><year>2020</year><volume>12</volume><issue>5</issue><elocation-id>513</elocation-id><pub-id pub-id-type="doi">10.3390/v12050513</pub-id><pub-id pub-id-type="pmid">32384820</pub-id><pub-id pub-id-type="pmcid">PMC7291041</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Stefanik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strakova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haviernik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Ruzek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eyer</surname><given-names>L.</given-names></name><article-title>Antiviral Activity
of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><issue>3</issue><elocation-id>471</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9030471</pub-id><pub-id pub-id-type="pmid">33668694</pub-id><pub-id pub-id-type="pmcid">PMC7996309</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>